



Messages and Communications for Doc. Nos. 36GL-22-1903 through 1911*.

1 message

Committee on Rules 36GL <cor@guamlegislature.org>
To: Clerks <clerks@guamlegislature.org>, Rennae Meno <rennae@guamlegislature.org>
Cc: "Speaker Therese M. Terlaje" <speaker@guamlegislature.org>

Wed, Apr 13, 2022 at 10:34 AM

Håfa Adai Clerks,

Please see attached M&C Doc. No. 36GL-22-1903 to 1911 for processing:

Table with 3 columns: Doc. No., Description, and Office of the Governor of Guam. Rows include bills 36GL-22-1903 through 36GL-22-1911.

Electronic and Hard Copies received and attached.

Si Yu'os Ma'åse',



COMMITTEE ON RULES

Vice Speaker Tina Rose Muña Barnes
36th Guam Legislature
I Mina'trentai Sais Na Liheslaturan Guåhan
163 Chalan Santo Papa Hågatña Guam 96910
Email: cor@guamlegislature.org

"Disclaimer: This message is intended only for the use of the individual or entity to which it is addressed and may contain information which is privileged, confidential, proprietary, or exempt from disclosure under applicable law. If you are not the intended recipient or the individual responsible for delivering the message to the intended recipient, you are strictly prohibited from disclosing, distributing, copying, or in any way using this message. If you have received this communication in error, please notify the sender and immediately delete any copies you may have received. Thank you."

----- Forwarded message -----
From: Speaker Therese M. Terlaje <speaker@guamlegislature.org>
Date: Wed, Apr 13, 2022 at 9:46 AM

Subject: Messages and Communications for 36GL-22-1903 to 1911

To: Legislative Secretary Amanda Shelton <officeofsenatorshelton@guamlegislature.org>, Committee on Rules 36GL <cor@guamlegislature.org>

Håfa Adai,

Please see attached M&C Doc. No. 36GL-22-1903 to 1911.*

36GL-22-1903	BILL NO. 169-36 (LS) nka P.L. No. 36-89 - An Act to Amend Appendix A, Appendix B, Appendix C, Appendix D, and Appendix E, All of Chapter 67, Title 9, Guam Code Annotated, Relative to Updating the List of Scheduled Controlled Substances Provided in the Guam Uniform Controlled Substances Act.*	Office of the Governor of Guam
36GL-22-1904	BILL NO. 247-36 (COR) nka P.L. No. 36-90 - An Act to Amend §§ 53101(d) and 53102, and to Add a New § 53109, All of Chapter 53, Title 11, Guam Code Annotated, Relative to Transferring the Authority to Implement the Guam Able Savings Program from the Department of Revenue and Taxation to the Department of Administration, and Authorizing the Governor to Identify and Transfer Up to Two Hundred Fifty Thousand Dollars (\$250,000) from the General Fund to Implement the Program.*	Office of the Governor of Guam
36GL-22-1905	SUBSTITUTE BILL NO. 213-36 (COR) nka P.L. No. 36-91 - An Act to Add New Subsections (a) and (b) to § 8119 of Article 1, Chapter 8, Title 12, Guam Code Annotated, Relative to Establishing an Exemption to the Guam Power Authority for the Construction of New Forty-One (41) Megawatt Ultra-Low Sulfur Diesel Units on Lots 261 and 257, U.S. Navy Apra Harbor Reservation, and be Required to Comply with the Air Quality and Emissions Limitations Contained in the U.S. Environmental Protection Agency Clean Air Act of 1990.*	Office of the Governor of Guam
36GL-22-1906	BILL NO. 224-36 (COR) nka P.L. No. 36-92 - An Act to Repeal Chapter 19, Division 3 of Title 30, Guam Administrative Rules and Regulations; and to Add a New Chapter 2 to Title 12, Guam Administrative Rules and Regulations, Relative to Clarifying Insurance Continuing Education.*	Office of the Governor of Guam
36GL-22-1907	SUBSTITUTE BILL NO. 41-36 (COR) nka P.L. No. 36-93 - An Act to Amend § 4210 of Article 2, Chapter 4, Title 19, Guam Code Annotated, Relative to Expediting Social Studies for Adoptions.*	Office of the Governor of Guam
36GL-22-1908	BILL NO. 68-36 (COR) nka P.L. No. 36-94 - An Act to Amend §§ 88103 and 88104, and to Add a New § 88103.1, All of Chapter 88, Title 5, Guam Code Annotated, Relative to Adding Youth Representation to I Kumision I Fino' CHamoru Yan I Fina'na'guen I Historia Yan I Lina'la' I Taotao Tano' (The Commission on CHamoru Language and the Teaching of the History and Culture of the Indigenous People of Guam), and Prohibiting Double Representation on I Kumision; and to Cite this Act as the "Mahoben Para I Fino'ta Act".*	Office of the Governor of Guam
36GL-22-1909	SUBSTITUTE BILL NO. 236-36 (COR) VETO - An Act to Amend § 5213 of Subarticle B, Article 3, Chapter 5, Title 5, Guam Code Annotated, Relative to Strengthening the Requirements of Small Purchases.*	Office of the Governor of Guam
36GL-22-1910	BILL NO. 123-36 (COR) VETO - An Act to Amend § 2108 of Chapter 2, Title 4, Guam Code Annotated, Relative to Requiring Employees Who Resign from Government of Guam Employment to Submit to Drug Testing to Retain Re-Employment Rights if said Resignation was Tendered Subsequent to the Employer's Announcement of Drug Testing.*	Office of the Governor of Guam
36GL-22-1911	BILL NO. 239-36 (COR) VETO - An Act to Add a New § 76206 to Article 2 of Chapter 76, Division 3, Title 11, Guam Code Annotated; and to Add a New § 13510 to Article 5 of Chapter 13, Title 19, Guam Code Annotated, Relative to Business License Requirements for Entities Engaging in Child Replacement Services.*	Office of the Governor of Guam

Note: e-Delivery received April 12, 2022 at 9:46 a.m. Hard copies received April 12, 2022 at 11:31 a.m.

Si Yu'os Ma'åse',

Marie Cruz
Community Relations Liaison

Office of Speaker Therese M. Terlaje
Committee on Health, Land, Justice and Culture
I Mina'trentai Sais na Liheslaturan Guåhan
36th Guam Legislature
Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910
T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com
website: www.senatorterlaje.com

----- Forwarded message -----

From: **Brianne LG Dunstan** <brianne.dunstan@guam.gov>

Date: Tue, Apr 12, 2022 at 9:46 AM

Subject: Statements regarding Legislative bills passed on: April 1, 2022

To: Speaker Therese M. Terlaje <speaker@guamlegislature.org>

Cc: GOVERNOR Lourdes A. Leon Guerrero <governor@guam.gov>, LT. GOVERNOR Joshua F. Tenorio <lt.governor@guam.gov>, Geraldine A. Cepeda <gcepeda@guamcourts.gov>, Guam Compiler of Laws <guamcompiler@gmail.com>, Lisa C. Ibanez <libanez@guamcourts.gov>, CHIEF OF STAFF Jon Junior Calvo <jon.calvo@guam.gov>, DEPUTY COS Alice Tajeron <alice.tajeron@guam.gov>, Legal <legal@guam.gov>, Stephanie G. Flores <stephanie.flores@guam.gov>, Krystal Paco-San Agustin <krystal.paco@guam.gov>, <lester.carlson@bbmr.guam.gov>, BERTHA <bertha.duenas@guam.gov>, Eliza G. Dames (Chamber) <eliza.dames@guam.gov>, Shamra L.A. Chargualaf (Chamber) <shamra.chargualaf@guam.gov>, Josephine C. Cepeda (Chamber) <josephine.cephed@guam.gov>, Kathleen C. Cepeda (COS) <kathleen.cephed@guam.gov>, Rhea Chang <rhea.chang@guam.gov>, Jessica Cruz (CF) <jessica.cruz@guam.gov>, BBMR Administrative Staff <admin@bbmr.guam.gov>, Analyn Eustaquio <analyn.eustaquio@bbmr.guam.gov>, Michael D. Weakley <michael.weakley@guam.gov>, Rikki Orsini <rikki.orsini@guam.gov>

Hafa Adai Madame Speaker,

Enclosed are copies of statements dated April 11, 2022, from the *Honorable*, Lourdes A. Leon Guerrero, regarding the following nine (9) bills:

- **BILL NO. 169-36 (LS) nka P.L. No. 36-89** – An Act to Amend Appendix A, Appendix B, Appendix C, Appendix D, and Appendix E, All of Chapter 67, Title 9, Guam Code Annotated, Relative to Updating the List of Scheduled Controlled Substances Provided in the Guam Uniform Controlled Substances Act
- **BILL NO. 247-36 (COR) nka P.L. No. 36-90** - An Act to Amend §§ 53101(d) and 53102, and to Add a New § 53109, All of Chapter 53, Title 11, Guam Code Annotated, Relative to Transferring the Authority to Implement the Guam Able Savings Program from the Department of Revenue and Taxation to the Department of Administration, and Authorizing the Governor to Identify and Transfer Up to Two Hundred Fifty Thousand Dollars (\$250,000) from the General Fund to Implement the Program
- **SUBSTITUTE BILL NO. 213-36 (COR) nka P.L. No. 36-91** - An Act to Add New Subsections (a) and (b) to § 8119 of Article 1, Chapter 8, Title 12, Guam Code Annotated, Relative to Establishing an Exemption to the Guam Power Authority for the Construction of New Forty-One (41) Megawatt Ultra-Low Sulfur Diesel Units on Lots 261 and 257, U.S. Navy Apra Harbor Reservation, and be Required to Comply with the Air Quality and Emissions Limitations Contained in the U.S. Environmental Protection Agency Clean Air Act of 1990
- **BILL NO. 224-36 (COR) nka P.L. No. 36-92** - An Act to Repeal Chapter 19, Division 3 of Title 30, Guam Administrative Rules and Regulations; and to Add a New Chapter 2 to Title 12, Guam Administrative Rules and Regulations, Relative to Clarifying Insurance Continuing Education
- **SUBSTITUTE BILL NO. 41-36 (COR) nka P.L. No. 36-93** - An Act to Amend § 4210 of Article 2, Chapter 4, Title 19, Guam Code Annotated, Relative to Expediting Social Studies for Adoptions
- **BILL NO. 68-36 (COR) nka P.L. No. 36-94** – An Act to Amend §§ 88103 and 88104, and to Add a New § 88103.1, All of Chapter 88, Title 5, Guam Code Annotated, Relative to Adding Youth Representation to I Kumision I Fino' CHamoru Yan I Fina'na'guen I Historia Yan I Lina'la' I Taotao Tano' (The Commission on CHamoru Language and the Teaching of the History and Culture of the Indigenous People of Guam), and Prohibiting Double Representation on I Kumision; and to Cite this Act as the "Mahoben Para I Fino'ta Act"
- **SUBSTITUTE BILL NO. 236-36 (COR) VETO** - An Act to Amend § 5213 of Subarticle B, Article 3, Chapter 5, Title 5, Guam Code Annotated, Relative to Strengthening the Requirements of Small Purchases
- **BILL NO. 123-36 (COR) VETO** - An Act to Amend § 2108 of Chapter 2, Title 4, Guam Code Annotated, Relative to Requiring Employees Who Resign from Government of Guam Employment to Submit to Drug Testing to Retain Re-Employment Rights if said Resignation was Tendered Subsequent to the Employer's Announcement of Drug Testing
- **BILL NO. 239-36 (COR) VETO** - An Act to Add a New § 76206 to Article 2 of Chapter 76, Division 3, Title 11, Guam Code Annotated; and to Add a New § 13510 to Article 5 of Chapter 13, Title 19, Guam Code Annotated, Relative to Business License Requirements for Entities Engaging in Child Replacement Services

The original statements and bills will be delivered to your office today.

Respectfully,

--



Brianne LG Dunstan

Unisifan I Maga'hågan Guåhan
Office of the Governor of Guam

Office of Legal Counsel

513 West Marine Corps Drive

Ricardo J. Bordallo Governor's Complex

Hagåtña, Guam 96910

Office: 671.473.1118

brianne.dunstan@guam.gov

9 attachments

36GL-22-1905.pdf
551K

36GL-22-1904.pdf
517K

36GL-22-1907.pdf
468K

36GL-22-1906.pdf
824K

36GL-22-1909.pdf
628K

36GL-22-1908.pdf
637K

36GL-22-1910.pdf
473K

36GL-22-1911.pdf
461K

36GL-22-1903.pdf
1945K



Speaker Therese M. Terlaje <speaker@guamlegislature.org>

Statements regarding Legislative bills passed on: April 1, 2022

Brianne LG Dunstan <brianne.dunstan@guam.gov> Tue, Apr 12, 2022 at 9:48 AM
 To: "Speaker Therese M. Terlaje" <speaker@guamlegislature.org>
 Cc: "GOVERNOR Lourdes A. Leon Guerrero" <governor@guam.gov>, "LT. GOVERNOR Joshua F. Tenorio" <lt.governor@guam.gov>, "Geraldine A. Cepeda" <gcepeda@guamcourts.gov>, Guam Compiler of Laws <guamcompiler@gmail.com>, "Lisa C. Ibanez" <libanez@guamcourts.gov>, CHIEF OF STAFF Jon Junior Calvo <jon.calvo@guam.gov>, DEPUTY COS Alice Taijeron <alice.taijeron@guam.gov>, Legal <legal@guam.gov>, "Stephanie G. Flores" <stephanie.flores@guam.gov>, Krystal Paco-San Agustin <krystal.paco@guam.gov>, lester.carlson@bbmr.guam.gov, BERTHA <bertha.duenas@guam.gov>, "Eliza G. Dames (Chamber)" <eliza.dames@guam.gov>, "Shamra L.A. Chargualaf (Chamber)" <shamra.chargualaf@guam.gov>, "Josephine C. Cepeda (Chamber)" <josephine.cepeda@guam.gov>, "Kathleen C. Cepeda (COS)" <kathleen.cepeda@guam.gov>, Rhea Chang <rhea.chang@guam.gov>, "Jessica Cruz (CF)" <jessica.cruz@guam.gov>, BBMR Administrative Staff <admin@bbmr.guam.gov>, Analyn Eustaquio <analyn.eustaquio@bbmr.guam.gov>, "Michael D. Weakley" <michael.weakley@guam.gov>, Rikki Orsini <rikki.orsini@guam.gov>

Hafa Adai Madame Speaker,

Enclosed are copies of statements dated April 11, 2022, from the *Honorable*, Lourdes A. Leon Guerrero, regarding the following nine (9) bills:

- **BILL NO. 169-36 (LS) nka P.L. No. 36-89** - An Act to Amend Appendix A, Appendix B, Appendix C, Appendix D, and Appendix E, All of Chapter 67, Title 9, Guam Code Annotated, Relative to Updating the List of Scheduled Controlled Substances Provided in the Guam Uniform Controlled Substances Act
- **BILL NO. 247-36 (COR) nka P.L. No. 36-90** - An Act to Amend §§ 53101(d) and 53102, and to Add a New § 53109, All of Chapter 53, Title 11, Guam Code Annotated, Relative to Transferring the Authority to Implement the Guam Able Savings Program from the Department of Revenue and Taxation to the Department of Administration, and Authorizing the Governor to Identify and Transfer Up to Two Hundred Fifty Thousand Dollars (\$250,000) from the General Fund to Implement the Program
- **SUBSTITUTE BILL NO. 213-36 (COR) nka P.L. No. 36-91** - An Act to Add New Subsections (a) and (b) to § 8119 of Article 1, Chapter 8, Title 12, Guam Code Annotated, Relative to Establishing an Exemption to the Guam Power Authority for the Construction of New Forty-One (41) Megawatt Ultra-Low Sulfur Diesel Units on Lots 261 and 257, U.S. Navy Apra Harbor Reservation, and be Required to Comply with the Air Quality and Emissions Limitations Contained in the U.S. Environmental Protection Agency Clean Air Act of 1990

- **BILL NO. 224-36 (COR) nka P.L. No. 36-92** - An Act to Repeal Chapter 19, Division 3 of Title 30, Guam Administrative Rules and Regulations; and to Add a New Chapter 2 to Title 12, Guam Administrative Rules and Regulations, Relative to Clarifying Insurance Continuing Education
- **SUBSTITUTE BILL NO. 41-36 (COR) nka P.L. No. 36-93** - An Act to Amend § 4210 of Article 2, Chapter 4, Title 19, Guam Code Annotated, Relative to Expediting Social Studies for Adoptions
- **BILL NO. 68-36 (COR) nka P.L. No. 36-94** – An Act to Amend §§ 88103 and 88104, and to Add a New § 88103.1, All of Chapter 88, Title 5, Guam Code Annotated, Relative to Adding Youth Representation to I Kumision I Fino' CHamoru Yan I Fina'na'guen I Historia Yan I Lina'la' I Taotao Tano' (The Commission on CHamoru Language and the Teaching of the History and Culture of the Indigenous People of Guam), and Prohibiting Double Representation on I Kumision; and to Cite this Act as the "Mahoben Para I Fino'ta Act"
- **SUBSTITUTE BILL NO. 236-36 (COR) VETO** - An Act to Amend § 5213 of Subarticle B, Article 3, Chapter 5, Title 5, Guam Code Annotated, Relative to Strengthening the Requirements of Small Purchases
- **BILL NO. 123-36 (COR) VETO** - An Act to Amend § 2108 of Chapter 2, Title 4, Guam Code Annotated, Relative to Requiring Employees Who Resign from Government of Guam Employment to Submit to Drug Testing to Retain Re-Employment Rights if said Resignation was Tendered Subsequent to the Employer's Announcement of Drug Testing
- **BILL NO. 239-36 (COR) VETO** - An Act to Add a New § 76206 to Article 2 of Chapter 76, Division 3, Title 11, Guam Code Annotated; and to Add a New § 13510 to Article 5 of Chapter 13, Title 19, Guam Code Annotated, Relative to Business License Requirements for Entities Engaging in Child Replacement Services

The original statements and bills will be delivered to your office today.

Respectfully,

--



Brianne LG Dunstan
 Unisifan I Maga'hågan Guåhan
 Office of the Governor of Guam
 Office of Legal Counsel
 513 West Marine Corps Drive
 Ricardo J. Bordallo Governor's Complex
 Hagåtña, Guam 96910
 Office: 671.473.1118
 brianne.dunstan@guam.gov

Doc Type: 36GL-22-1903-1911
 OFFICE OF THE SPEAKER
 THERESE M. TERLAJE

04-12-2022

Time: 9:46 a.m.
 Received: [Signature]

COMMITTEE ON RULES





RECEIVED:

April 13, 2022

9:46 A.M.

[Signature]

9 attachments

 Bill No. 247-36 (COR) nka P.L. 36-90.pdf 169K	<i>36GL-22-1904</i>
 Sub. Bill No. 213-36 (COR) nka P.L. 36-91.pdf 187K	<i>36GL-22-1905</i>
 Bill No. 224-36 (COR) nka P.L. 36-92.pdf 314K	<i>36GL-22-1906</i>
 Sub. Bill No. 41-36 (COR) nka P.L. 36-93.pdf 144K	<i>36GL-22-1907</i>
 Bill No. 68-36 (COR) nka P.L. 36-94.pdf 226K	<i>36GL-22-1908</i>
 Sub. Bill No. 236-36 (COR)_VETO.pdf 225K	<i>36GL-22-1909</i>
 Bill No. 123-36 (COR)_VETO.pdf 148K	<i>36GL-22-1910</i>
 Bill No. 239-36 (COR)_VETO.pdf 135K	<i>36GL-22-1911</i>
 Bill No. 169-36 (LS) nka P.L. 36-89.pdf 853K	<i>36GL-22-1903</i>

LOURDES A. LEON GUERRERO
GOVERNOR



JOSHUA F. TENORIO
LT. GOVERNOR

UFISINAN I MAGA'HĀGAN GUĀHAN
OFFICE OF THE GOVERNOR OF GUAM

April 11, 2022

HONORABLE THERESE M. TERLAJE, *Speaker*
I Mina'trentai Sais Na Liheslaturan Guåhan
36th Guam Legislature
Guam Congress Building
163 Chalan Santo Papa
Hagåtña, Guam 96910

Re: BILL NO. 169-36 (LS) – AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E, ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT

Hafa Adai Madame Speaker,

The number of new illegal synthetic drugs being produced is constantly increasing. Development of new drugs is the criminal's method of attempting to avoid prosecution, by creating a chemical compound that is not currently prohibited by the Controlled Substances Act. As new dangerous drugs are developed, law enforcement must be able to protect the citizens of Guam from the individuals who produce, transport, and sell them. Prosecution of individuals involved in the distribution chain of new drugs is only possible if the Controlled Substances Act is kept up to date by identifying new drugs and including them in the schedules of compounds that are illegal to produce, sell, or possess in Guam. Bill 169-36 accomplishes this by updating the appendices of the Guam Uniform Controlled Substances Act. I hereby sign Bill No.169-36 into law as **Public Law No. 36-89**.

Senseremente,

LOURDES A. LEON GUERRERO
Maga'hāgan Guåhan
Governor of Guam


Enclosure: Bill No. 169-36 (LS) *nka P.L. No. 36-89*

cc via email: *Honorable* Joshua F. Tenorio, *Sigundo Maga'låhen Guåhan*
Compiler of Laws

I MINA'TRENTAI SAIS NA LIHESLATURAN GUÅHAN
2022 (SECOND) Regular Session

CERTIFICATION OF PASSAGE OF AN ACT TO *I MAGA'HÅGAN GUÅHAN*

This is to certify that **Bill No. 169-36 (LS)**, “**AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E, ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT,**” was on the 1st day of April 2022, duly and regularly passed.




Therese M. Terlaje
Speaker

Attested:




Amanda L. Shelton
Legislative Secretary

This Act was received by *I Maga'hågan Guåhan* this 1 day of April,
2022, at 9:39 o'clock P.M.



Assistant Staff Officer
Maga'håga's Office

APPROVED:



Lourdes A. Leon Guerrero
I Maga'hågan Guåhan

Date: 4/11/2022

Public Law No. 36-89

2022-16197
RCUD AT CENTRAL FILE!
APR 4 '22 AM 9:01

Elaine Tajalle

I MINA'TRENTAI SAIS NA LIHESLATURAN GUÅHAN
2021 (FIRST) Regular Session

Bill No. 169-36 (LS)

As amended by the Committee on Health,
Land, Justice, and Culture.

Introduced by:

Telena Cruz Nelson
V. Anthony Ada
Frank Blas Jr.
Joanne Brown
Christopher M. Dueñas
James C. Moylan
Tina Rose Muña Barnes
Sabina Flores Perez
Clynton E. Ridgell
Joe S. San Agustin
Amanda L. Shelton
Telo T. Taitague
Jose "Pedo" Terlaje
Therese M. Terlaje
Mary Camacho Torres

**AN ACT TO *AMEND* APPENDIX A, APPENDIX B,
APPENDIX C, APPENDIX D, AND APPENDIX E, ALL OF
CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED,
RELATIVE TO UPDATING THE LIST OF SCHEDULED
CONTROLLED SUBSTANCES PROVIDED IN THE
GUAM UNIFORM CONTROLLED SUBSTANCES ACT.**

1 **BE IT ENACTED BY THE PEOPLE OF GUAM:**

2 **Section 1. Legislative Findings and Intent.** *I Liheslaturan Guåhan* finds
3 that the continued health and public safety of the people of Guam necessitates a
4 unified legal framework that regulates the use, dispensation, and categorization of

1 controlled substances. The purpose of this Act is to update Schedule I through
2 Schedule V of controlled substances based on their medical utility and potential for
3 dependence or abuse.

4 *I Liheslaturan Guåhan* further finds that the Department of Public Health and
5 Social Services (DPHSS) has the authority to administer this Act and to add, delete,
6 or otherwise update Appendices A, B, C, D, and E in accordance with § 67.201 of
7 Chapter 67, Title 9, Guam Code Annotated. The following updated lists of controlled
8 substances are in accordance with DPHSS's findings and research.

9 It is, therefore, the intent of *I Liheslaturan Guåhan* and DPHSS to properly
10 update the list of scheduled drugs to reflect federal regulations provided in §1308.11,
11 §1308.12, §1308.13, §1308.14, and §1308.15 of Title 21, U.S. Code of Federal
12 Regulations, relative to schedules of controlled substances.

13 **Section 2.** APPENDIX A of Chapter 67, Title 9, Guam Code Annotated, is
14 hereby *amended* to read:

15 “(a) Opiates. Any of the following opiates, including their isomers,
16 esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the
17 existence of such isomers, esters, ethers and salts is possible within the
18 specific chemical designation (for purposes of 3-methylthiofentanyl only, the
19 term isomer includes the optical and geometric isomers):

20 (1) acetyl-alpha-methylfentanyl (*N*-[1-(1-methyl-2-
21 phenethyl)-4-piperidinyl]-*N*-phenylacetamide);

22 (2) acetylmethadol;

23 (3) acetyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
24 phenylacetamide);

25 (4) acryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
26 phenylacrylamide; also known as: acryloylfentanyl);

- 1 (5) AH-7921 (3,4-dichloro-*N*-[(1-dimethylamino)
2 cyclohexylmethyl]benzamide);
3 (6) allylprodine;
4 (7) alphacetylmethadol (except levoalphacetylmethadol also
5 known as levo-alpha-acetylmethadol, levomethadyl acetate, or
6 LAAM);
7 (8) alphameprodine;
8 (9) alphamethadol;
9 (10) alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)
10 ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
11 propanilido) piperidine);
12 (11) alpha-methylthiofentanyl (*N*-[1-methyl-2-(2-
13 thienyl)ethyl-4-piperidinyl]-*N*-phenylpropanamide);
14 (12) benzethidine;
15 (13) betacetylmethadol;
16 (14) beta-hydroxyfentanyl (*N*-[1-(2-hydroxy-2-phenethyl)-4-
17 piperidinyl]-*N*-phenylpropanamide);
18 (15) beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
19 phenethyl)-3-methyl-4-piperidinyl]-*N*-phenylpropanamide);
20 (16) *beta*-Hydroxythiofentanyl *N*-[1-[2-hydroxy-2-(thiophen-
21 2-yl)ethyl]piperidin-4-yl]-*N*-phenylpropionamide ;
22 (17) betameprodine;
23 (18) betamethadol;
24 (19) betaprodine;
25 (20) butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-*N*-
26 phenylbutyramide);
27 (21) clonitazene;

- 1 (22) cyclopropyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
2 phenylcyclopropanecarboxamide);
- 3 (23) dextromoramide;
- 4 (24) diampromide;
- 5 (25) diethylthiambutene;
- 6 (26) difenoxin;
- 7 (27) dimenoxadol;
- 8 (28) dimepheptanol;
- 9 (29) dimethylthiambutene;
- 10 (30) dioxaphetyl butyrate;
- 11 (31) dipipanone;
- 12 (32) ethylmethylthiambutene;
- 13 (33) etonitazene;
- 14 (34) etoxeridine;
- 15 (35) 4-Fluoroisobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-
16 phenethylpiperidin-4-yl)isobutyramide; also known as: *para*-
17 fluoroisobutyryl fentanyl);
- 18 (36) furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
19 phenylfuran-2-carboxamide);
- 20 (37) furethidine;
- 21 (38) hydroxypethidine;
- 22 (39) ketobemidone;
- 23 (40) levomoramide;
- 24 (41) levophenacilmorphan;
- 25 (42) methoxyacetyl fentanyl (2-methoxy-*N*-(1-
26 phenethylpiperidin-4-yl)-*N*-phenylacetamide);

- 1 (43) 3-methylfentanyl (*N*-[3-methyl-1-(2-phenylethyl)-4-
2 piperidyl]-*N*-phenylpropanamide);
- 3 (44) 3-methylthiofentanyl (*N*-[3-methyl-1-(2- thienylethyl)-4-
4 piperidiny]l)-*N*-phenylpropanamide);
- 5 (45) morpheridine;
- 6 (46) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 7 (47) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl) piperazine);
- 8 (48) noracymethadol;
- 9 (49) norlevorphanol;
- 10 (50) normethadone;
- 11 (51) norpipanone;
- 12 (52) ocfentanil (*N*-(2-fluorophenyl)-2-methoxy-*N*-(1-
13 phenethylpiperidin-4-yl)acetamide);
- 14 (53) *ortho*-Fluorofentanyl (*N*-(2-fluorophenyl)-*N*-(1-
15 phenethylpiperidin-4-yl)propionamide); also known as: 2-
16 fluorofentanyl;
- 17 (54) *para*-Fluorobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-
18 phenethylpiperidin-4-yl)butyramide);
- 19 (55) *para*-fluorofentanyl (*N*-(4-fluorophenyl)-*N*-[1-(2-
20 phenethyl)-4-piperidiny]l]propanamide;
- 21 (56) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 22 (57) phenadoxone;
- 23 (58) phenampromide;
- 24 (59) phenomorphan;
- 25 (60) phenoperidine;
- 26 (61) piritramide;
- 27 (62) proheptazine;

- 1 (63) properidine;
- 2 (64) propiram;
- 3 (65) racemoramide;
- 4 (66) tetrahydrofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-
- 5 yl)-*N*-phenyltetrahydrofuran-2-carboxamide);
- 6 (67) thiofentanyl (*N*-phenyl-*N*-[1-(2-thienyl)ethyl-4-
- 7 piperidiny]-propanamide);
- 8 (68) tilidine;
- 9 (69) trimeperidine; and
- 10 (70) U-47700(3,4-Dichloro-*N*-[2-
- 11 (dimethylamino)cyclohexyl]-*N*-methylbenzamide).

12 (b) Opium derivatives. Any of the following opium derivatives, its
13 salts, isomers and salts of isomers whenever the existence of such salts,
14 isomers, and salts of isomers is possible within the specific chemical
15 designation:

- 16 (1) acetorphine;
- 17 (2) acetyldihydrocodeine;
- 18 (3) benzylmorphine;
- 19 (4) codeine methylbromide;
- 20 (5) codeine-*N*-Oxide;
- 21 (6) cyprenorphine;
- 22 (7) desomorphine;
- 23 (8) dihydromorphine;
- 24 (9) drotebanol;
- 25 (10) etorphine (except hydrochloride salt);
- 26 (11) heroin;
- 27 (12) hydromorphanol;

- 1 (13) methyldesorphine;
- 2 (14) methyldihydromorphine;
- 3 (15) morphine methylbromide;
- 4 (16) morphine methylsulfonate;
- 5 (17) morphine-N-oxide;
- 6 (18) myrophine;
- 7 (19) nicocodeine;
- 8 (20) nicomorphine;
- 9 (21) normorphine;
- 10 (22) pholcodine; and
- 11 (23) thebacon.

12 (c) Hallucinogenic substances. Any material, compound, mixture, or
13 preparation which contains any quantity of the following hallucinogenic
14 substances, or which contains any of its salts, isomers, and salts of isomers
15 whenever the existence of such salts, isomers, and salts of isomers is possible
16 within the specific chemical designation (for purposes of this paragraph only,
17 the term "isomer" includes the optical, position and geometric isomers):

- 18 (1) Alpha-ethyltryptamine (some trade or other names:
19 etryptamine; Monase; α -ethyl-1H-indole-3-ethanamine; 3-(2-
20 aminobutyl) indole; α -ET; and AET);
- 21 (2) 4-bromo-2,5-dimethoxy-amphetamine (some trade or
22 other names: 4-bromo-2,5-dimethoxy- α -methylphenethylamine;
23 4-bromo-2,5-DMA);
- 24 (3) 4-Bromo-2,5-dimethoxyphenethylamine (some trade or
25 other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-
26 desmethyl DOB; 2C-B, Nexus);

- 1 (4) 2,5-dimethoxyamphetamine (some trade or other names:
2 2,5-dimethoxy- α -methylphenethylamine; 2,5-DMA);
- 3 (5) 2,5-dimethoxy-4-ethylamphet-amine (some trade or other
4 name: DOET);
- 5 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other
6 name: 2C-T-7);
- 7 (7) 4-methoxyamphetamine (some trade or other names: 4-
8 methoxy- α -methylphenethylamine; paramethoxyamphetamine, PMA);
- 9 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 10 (9) 4-methyl-2,5-dimethoxy-amphetamine (some trade or
11 other names: 4-methyl-2,5-dimethoxy- α -methylphenethylamine;
12 “DOM”; and “STP”);
- 13 (10) 3,4-methylenedioxy amphetamine;
- 14 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 15 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known
16 as: N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-
17 ethyl MDA, MDE, MDEA);
- 18 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also
19 known as: N-hydroxy-alpha-methyl-3,4(methylenedioxy)-
20 phenethylamine, and N-hydroxy MDA);
- 21 (14) 3,4,5-trimethoxy amphetamine;
- 22 (15) 5-methoxy-N,N-dimethyltryptamine (some trade or other
23 names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT;
- 24 (16) Alpha-methyltryptamine (other name: AMT);
- 25 (17) bufotenine (some trade or other names: 3-(β -
26 Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-

1 indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;
2 mappine);

3 (18) diethyltryptamine (some trade or other names: N,N-
4 Diethyltryptamine; DET);

5 (19) dimethyltryptamine (some trade or other name: DMT);

6 (20) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-
7 MeO-DIPT);

8 (21) ibogaine (some trade or other names: 7-Ethyl-
9 6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido
10 [1',2':1,2] azepino [5,4-b] indole; Tabernanthe iboga);

11 (22) lysergic acid diethylamide;

12 (23) [Repealed];

13 (24) mescaline;

14 (25) parahexyl-7374(some trade or other names: 3-Hexyl-1-
15 hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
16 Synhexyl);

17 (26) peyote (meaning all parts of the plant presently classified
18 botanically as *Lophophora williamsii* Lemaire, whether growing or not,
19 the seeds thereof, any extract from any part of such plant, and every
20 compound, manufacture, salts, derivative, mixture, or preparation of
21 such plant, its seeds or extracts);

22 (27) N-ethyl-3-piperidyl benzilate;

23 (28) N-methyl-3-piperidyl benzilate;

24 (29) psilocybin;

25 (30) psilocyn;

26 (31) [Repealed];

1 (32) ethylamine analog of phencyclidine (some trade or other
2 names: N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)
3 ethylamine, N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE);

4 (33) pyrrolidine analog of phencyclidine (some trade or other
5 names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);

6 (34) thiophene analog of phencyclidine (some trade or other
7 names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of
8 phencyclidine, TPCP, TCP);

9 (35) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (some other
10 names: TCPy)

11 (36) 4-methylmethcathinone (Mephedrone);

12 (37) 3,4-methylenedioxyprovalerone (MDPV);

13 (38) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E);

14 (39) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D);

15 (40) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C);

16 (41) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I);

17 (42) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl] ethanamine (2C-
18 T-2);

19 (43) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine
20 (2C-T-4);

21 (44) 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H);

22 (45) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N);

23 (46) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-
24 P);

25 (47) 3,4-Methylenedioxy-N-methylcathinone (Methylone);

26 (48) (1-pentyl-1*H*-indol-3-yl) (2,2,3,3-
27 tetramethylcyclopropyl) methanone (UR-144);

- 1 (49) [1-(5-fluoro-pentyl)-1*H*-indol-3-yl](2,2,3,3-
2 tetramethylcyclopropyl) methanone (5-fluoro-UR-144, XLR11);
3 (50) *N*-(1-adamantyl)-1-pentyl-1*H*-indazole-3-carboxamide
4 (APINACA, AKB48);
5 (51) quinolin-8-yl 1-pentyl-1*H*-indole-3-carboxylate (PB-22;
6 QUPIC);
7 (52) quinolin-8-yl 1-(5-fluoropentyl)-1*H*-indole-3-carboxylate
8 (5-fluoro-PB-22; 5F-PB-22);
9 (53) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
10 fluorobenzyl)-1*H*-indazole-3-carboxamide (AB-FUBINACA);
11 (54) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-
12 indazole-3-carboxamide (ADB-PINACA);
13 (55) 2-(4-iodo-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
14 ethanamine (25I-NBOMe, 2C-I-NBOMe);
15 (56) 2-(4-chloro-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
16 ethanamine (25C-NBOMe, 2C-C-NBOMe);
17 (57) 2-(4-bromo-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
18 ethanamine (25B-NBOMe, 2C-B-NBOMe);
19 (58) 4-methyl-*N*-ethylcathinone (4-MEC);
20 (59) 4-methyl-*alpha*-pyrrolidinopropiophenone(4-MePPP);
21 (60) *alpha*-pyrrolidinopentiophenone (α -PVP);
22 (61) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
23 (butylone, bk-MBDB);
24 (62) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
25 (63) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one
26 (pentylone, bk-MBDB);
27 (64) 4-fluoro-*N*-methylcathinone (4-FMC; flephedrone);

- 1 (65) 3-fluoro-*N*-methylcathinone (3-FMC);
- 2 (66) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one
3 (naphyrone);
- 4 (67) alpha-pyrrolidinobutiophenone (α -PBP);
- 5 (68) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
6 (cyclohexylmethyl)-1*H*-indazole-3-carboxamide (AB-CHMINACA);
- 7 (69) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1*H*-
8 indazole-3-carboxamide (AB-PINACA);
- 9 (70) [1-(5-fluoropentyl)-1*H*-indazol-3-yl](naphthalen-1-
10 yl)methanone (THJ-2201);
- 11 (71) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
12 (cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-
13 CHMINACA; ADB- CHMINACA);
- 14 (72) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-
15 carboxamido)-3,3-dimethylbutanoate (Other names: 5F-ADB; 5F-
16 MDMB-PINACA);
- 17 (73) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-
18 carboxamido)-3-methylbutanoate (Other names: 5F-AMB);
- 19 (74) *N*-(adamantan-1-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-
20 carboxamide (Other names: 5F-APINACA, 5F-AKB48);
- 21 (75) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-
22 fluorobenzyl)-1*H*-indazole-3-carboxamide (Other names: ADB-
23 FUBINACA);
- 24 (76) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-
25 carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-
26 CHMICA, MMB-CHMINACA);

1 (77) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-
2 carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-
3 FUBINACA); and

4 (78) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-
5 carboxamido)-3-methylbutanoate, (FUB-AMB, MMB-FUBINACA,
6 AMB-FUBINACA).

7 (d) Depressants. Any material, compound, mixture or preparation
8 which contains any quantity of the following substances having a depressant
9 effect on the central nervous system, including its salts, isomers and salts of
10 isomers whenever the existence of such salts, isomers, and salts of isomers is
11 possible within the specific chemical designation:

12 (1) gamma-hydroxybutyric acid (some other names include
13 GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-
14 hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

15 (2) mecloqualone; and

16 (3) methaqualone.

17 (e) *Stimulants*. Any material, compound, mixture, or preparation
18 which contains any quantity of the following substances having a stimulant
19 effect on the central nervous system, including its salts, isomers and salts of
20 isomers:

21 (1) Aminorex (other names: aminoxaphen; 2-amino-5-
22 phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine);

23 (2) N-Benzylpiperazine (other names: BZP, 1-
24 benzylpiperazine);

25 (3) Cathinone (other names: 2-amino-1-phenyl-1-
26 propanone; alpha-aminopropiophenone; 2-aminopropiophenone; and
27 norephedrone);

- 1 (4) Fenethylamine;
- 2 (5) Methcathinone (other names: 2-(methylamino)-
3 propiophenone; alpha-(methylamino)propiophenone; 2-
4 (methylamino)-1-phenylpropan-1-one; alpha-*N*-
5 methylaminopropiophenone; monomethylpropion; ephedrone; *N*-
6 methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and
7 UR1432), its salts, optical isomers and salts of optical isomers);
- 8 (6) (\pm)*cis*-4-methylaminorex (other name: (\pm)*cis*-4,5-
9 dihydro-4-methyl-5-phenyl-2-oxazoline);
- 10 (7) *N*-ethylamphetamine; and
- 11 (8) *N,N*-dimethylamphetamine (also known as *N,N*-alpha-
12 trimethyl-benzeneethanamine; *N,N*-alpha-trimethylphenethylamine).
- 13 (f) *Cannabimimetic agents*. Any material, compound, mixture or
14 preparation which contains any quantity of the following substances or which
15 contains their salts, isomers, and salts of isomers whenever the existence of
16 such salts, isomers, and salts of isomers is possible within the specific
17 chemical designation:
- 18 (1) 5-(1,1-dimethylheptyl)-2-[(1*R*,3*S*)-3-
19 hydroxycyclohexyl]-phenol CP-47,497);
- 20 (2) 5-(1,1-dimethyloctyl)-2-[(1*R*,3*S*)-3-hydroxycyclohexyl]-
21 phenol, (cannabicyclohexanol or CP-47,497 C8-homolog);
- 22 (3) 1-Butyl-3-(1-naphthoyl)indole, its optical, positional, and
23 geometric isomers, salts and salts of isomers (other names: JWH-073);
- 24 (4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole, its
25 optical, positional, and geometric isomers, salts and salts of isomers
26 (other names: JWH-200);

1 (5) 1-Pentyl-3-(1-naphthoyl)indole, its optical, positional, and
2 geometric isomers, salts and salts of isomers (other names: JWH-018
3 and AM678);

4 (6) *Salvia divinorum* or *Salvinorum A*; all parts of the plant
5 presently classified botanically as *Salvia divinorum*, whether growing
6 or not, the seeds thereof, any extract from any part of such plant, and
7 every compound, manufacture, salts, derivative, mixture, or
8 preparation of such plant, its seeds or extracts;

9 (7) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);

10 (8) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);

11 (9) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);

12 (10) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

13 (11) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

14 (12) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);

15 (13) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);

16 (14) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and
17 RCS-4);

18 (15) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole
19 7008(SR-18 and RCS-8);

20 (16) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); and

21 (17) any synthetic cannabinoid.

22 (g) Temporary listing of substances subject to emergency
23 scheduling. Any material, compound, mixture or preparation which contains
24 any quantity of the following substances:

25 (1) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide, its
26 isomers, esters, ethers, salts and salts of isomers, esters and ethers (other
27 name: valeryl fentanyl);

1 (2) *N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-
2 yl)butyramide, its isomers, esters, ethers, salts and salts of isomers,
3 esters and ethers (other name: *para*-methoxybutyryl fentanyl);

4 (3) *N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-
5 yl)isobutyramide, its isomers, esters, ethers, salts and salts of isomers,
6 esters and ethers (other name: *para*-chloroisobutyryl fentanyl);

7 (4) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide,
8 its isomers, esters, ethers, salts and salts of isomers, esters and ethers
9 (other name: isobutyryl fentanyl);

10 (5) *N*-(1-phenethylpiperidin-4-yl)-*N*-
11 phenylcyclopentanecarboxamide, its isomers, esters, ethers, salts and
12 salts of isomers, esters and ethers (other name: cyclopentyl fentanyl);

13 (6) Naphthalen-1-yl 1-(5-fluoropentyl)-1*H*-indole-3-
14 carboxylate, its optical, positional, and geometric isomers, salts and
15 salts of isomers (other names: NM2201; CBL2201);

16 (7) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
17 fluoropentyl)-1*H*-indazole-3-carboxamide, its optical, positional, and
18 geometric isomers, salts and salts of isomers (other names: 5F-AB-
19 PINACA);

20 (8) 1-(4-cyanobutyl)-*N*-(2-phenylpropan-2-yl)-1*H*-indazole-
21 3-carboximide, its optical, positional, and geometric isomers, salts and
22 salts of isomers (other names: 4-CN-CUMYL-BUTINACA; 4-cyano-
23 CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-
24 BINACA; SGT-78);

25 (9) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-
26 carboxamido)-3-methylbutanoate, its optical, positional, and

1 geometric isomers, salts and salts of isomers (other names: MMB-
2 CHMICA, AMB- CHMICA);

3 (10) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-
4 pyrrolo[2,3-*b*]pyridine-3-carboxamide, its optical, positional, and
5 geometric isomers, salts and salts of isomers (other names: 5F-
6 CUMYL- P7AICA);

7 (11) *N*-Ethylpentylone, its optical, positional, and geometric
8 isomers, salts and salts of isomers (other names: ephylone, 1-(1,3-
9 benzodioxol-5-yl)- 2-(ethylamino)-pentan-1-one);

10 (12) ethyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-
11 3,3-dimethylbutanoate, its optical, positional, and geometric isomers,
12 salts and salts of isomers (trivial name: 5F-EDMB-PINACA);

13 (13) methyl 2-(1-(5-fluoropentyl)-1*H*-indole-3-carboxamido)-
14 3,3-dimethylbutanoate, its optical, positional, and geometric isomers,
15 salts and salts of isomers (trivial name: 5F-MDMB-PICA);

16 (14) *N*-(adamantan-1-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-
17 carboxamide, its optical, positional, and geometric isomers, salts and
18 salts of isomers (trivial names: FUB-AKB48; FUB-APINACA; AKB48
19 *N*-(4-FLUOROBENZYL));

20 (15) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-
21 indazole-3-carboxamide, its optical, positional, and geometric isomers,
22 salts and salts of isomers (trivial names: 5F-CUMYL-PINACA; SGT-
23 25);

24 (16) (1-(4-fluorobenzyl)-1*H*-indol-3-yl)(2,2,3,3-
25 tetramethylcyclopropyl) methanone, its optical, positional, and
26 geometric isomers, salts and salts of isomers (trivial name: FUB-144);

1 (17) *N*-Ethylhexedrone, its optical, positional, and geometric
2 isomers, salts and salts of isomers (Other name: 2-(ethylamino)-1-
3 phenylhexan-1-one;

4 (18) *alpha*-Pyrrolidinohexanophenone, its optical, positional,
5 and geometric isomers, salts and salts of isomers (Other names: α -PHP;
6 *alpha*-pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidine-1-yl)hexan-
7 1-one);

8 (19) 4-Methyl-*alpha*-ethylaminopentiophenone, its optical,
9 positional, and geometric isomers, salts and salts of isomers (Other
10 names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);

11 (20) 4-Methyl-*alpha*-pyrrolidinohexiophenone, its
12 optical, positional, and geometric isomers, salts and salts of
13 isomers (Other names: MPHP; 4-methyl-*alpha*-
14 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidine-1-
15 yl)hexan-1-one);

16 (21) *alpha*-Pyrrolidinoheptaphenone, its optical, positional,
17 and geometric isomers, salts and salts of isomers (Other names: PV8;
18 1-phenyl-2-(pyrrolidine-1-yl)heptan-1-one); and

19 (22) 4'-Chloro-*alpha*-pyrrolidinovalerophenone, its optical,
20 positional, and geometric isomers, salts and salts of isomers (Other
21 names: 4-chloro- α -PVP; 4'-chloro-*alpha*-pyrrolidinopentiophenone; 1-
22 (4-chlorophenyl)-2-(pyrrolidine-1-yl)pentan-1-one)."

23 **Section 3.** APPENDIX B of Chapter 67, Title 9, Guam Code Annotated, is
24 hereby *amended* to read:

25 "(a) Substances, vegetable origin or chemical synthesis. Any of the
26 following substances whether produced directly or indirectly by extraction

1 from substances of vegetable origin, or independently by means of chemical
2 synthesis, or by a combination of extraction and chemical synthesis:

3 (1) Opium and opiate, and any salt, compound, derivative, or
4 preparation of opium or opiate excluding apomorphine, thebaine-
5 derived butorphanol, dextrorphan, nalbuphine, naldemedine,
6 nalmefene, naloxegol, naloxone, 6 β -naltrexol and naltrexone, and their
7 respective salts, but including the following:

- 8 (A) codeine;
- 9 (B) dihydroetorphine;
- 10 (C) ethylmorphine;
- 11 (D) etorphine hydrochloride;
- 12 (E) granulated opium;
- 13 (F) hydrocodone;
- 14 (G) hydromorphone;
- 15 (H) metopon;
- 16 (I) morphine;
- 17 (J) noroxymorphone;
- 18 (K) opium extracts;
- 19 (L) opium fluid;
- 20 (M) oripavine;
- 21 (N) oxycodone;
- 22 (O) oxymorphone;
- 23 (P) powdered opium;
- 24 (Q) raw opium;
- 25 (R) thebaine; and
- 26 (S) tincture of opium.

1 (2) Any salt, compound, derivative, or preparation thereof
2 which is chemically equivalent or identical with any of the substances
3 listed in Subsection (a)(1) of this Section, except that these substances
4 shall not include the isoquinoline alkaloids of opium;

5 (3) Opium poppy and poppy straw;

6 (4) Coca leaves and any salt, compound, derivative, or
7 preparation of coca leaves, (including cocaine and ecgonine and their
8 salts, isomers, derivatives, and salts of isomers and derivatives), and
9 any salt, compound, derivative, or preparation thereof which is
10 chemically equivalent or identical with any of these substances, except
11 that the substances shall not include:

12 (A) decocainized coca leaves or extraction of coca
13 leaves, which extractions do not contain cocaine or ecgonine; or

14 (B) ioflupane.

15 (5) Concentrate of poppy straw (the crude extract of poppy
16 straw in either liquid, solid, or powder form which contains the
17 phenanthrene alkaloids of the opium poppy).

18 (b) Opiates. Any of the following opiates, including its isomers,
19 esters, ethers, salts, and salts of isomers, esters, and ethers whenever the
20 existence of such isomers, esters, ethers, and salts is possible within the
21 specific chemical designation, dextrorphan and levopropoxyphene excepted:

22 (1) alfentanil;

23 (2) alphaprodine;

24 (3) anileridine;

25 (4) bezitramide;

26 (5) bulk dextropropoxyphene (non-dosage forms);

27 (6) carfentanil;

- 1 (7) dihydrocodeine;
- 2 (8) diphenoxylate;
- 3 (9) fentanyl;
- 4 (10) isomethadone;
- 5 (11) levo-alpha-acetylmethadol [some other names: levo-alpha-
- 6 acetylmethadol, levomethadyl acetate, LAAM];
- 7 (12) levomethorphan;
- 8 (13) levorphanol;
- 9 (14) metazocine;
- 10 (15) methadone;
- 11 (16) methadone-intermediate, 4-cyano-2-dimethylamino-4,4-
- 12 diphenyl butane;
- 13 (17) moramide-intermediate, 2-methyl-3-morpholino-1, 1-
- 14 diphenylpropane-carboxylic acid;
- 15 (18) pethidine (meperidine);
- 16 (19) pethidine-intermediate-A, 4-cyano-1-methyl-4-
- 17 phenylpiperidine;
- 18 (20) pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-
- 19 carboxylate;
- 20 (21) pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-
- 21 4-carboxylic acid;
- 22 (22) phenazocine;
- 23 (23) piminodine;
- 24 (24) racemethorphan;
- 25 (25) racemorphan;
- 26 (26) remifentanil;
- 27 (27) sufentanil;

1 (28) tapentadol; and

2 (29) thiafentanil.

3 (c) Stimulants. Any material, compound, mixture, or preparation
4 which contains any quantity of the following substances having a stimulant
5 effect on the central nervous system:

6 (1) amphetamine, its salts, optical isomers, and salts of its
7 optical isomers;

8 (2) methamphetamine, its salts, isomers, and salts of its
9 isomers;

10 (3) phenmetrazine and its salts;

11 (4) methylphenidate; and

12 (5) lisdexamfetamine, its salts, isomers, and salts of its
13 isomers.

14 (d) Depressants. Any material, compound, mixture, or preparation
15 which contains any quantity of the following substances having a depressant
16 effect on the central nervous system, including its salts, isomers, and salts of
17 isomers whenever the existence of such salts, isomers, and salts of isomers is
18 possible within the specific chemical designation:

19 (1) amobarbital;

20 (2) pentobarbital;

21 (3) phencyclidine;

22 (4) secobarbital; and

23 (5) glutethimide;

24 (e) Hallucinogenic substances.

25 (1) Nabilone (other name for nabilone: (±)-trans-3-(1,1-
26 dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-
27 9H-dibenzo[b,d] pyran-9-one).

1 (f) Immediate precursors. Any material, compound, mixture, or
2 preparation containing any quantity of the following substances:

3 (1) Immediate precursor to amphetamine and
4 methamphetamine:

5 (A) phenylacetone (other names: phenyl-2-propanone;
6 P2P; benzyl methyl ketone; methyl benzyl ketone);

7 (2) Immediate precursors to phencyclidine (PCP):

8 (A) 1-phenylcyclohexylamine; and

9 (B) 1-piperidinocyclohexanecarbonitrile (PCC).

10 (3) Immediate precursor to fentanyl:

11 (A) 4-anilino-N-phenethylpiperidine (ANPP).”

12 **Section 4.** APPENDIX C of Chapter 67, Title 9, Guam Code Annotated, is
13 hereby *amended* to read:

14 “(a) Stimulants. Any material, compound, mixture, or preparation
15 which contains any quantity of the following substances having a stimulant
16 effect on the central nervous system, including its salts, isomers (whether
17 optical, positional, or geometric), and salts of such isomers whenever the
18 existence of such salts, isomers, and salts of isomers is possible within the
19 specific chemical designation:

20 (1) Those compounds, mixtures, or preparations in dosage
21 unit form containing any stimulant substance included in Schedule II
22 which compounds, mixtures, or preparations were listed as an
23 excepted compound on August 25, 1971, pursuant to the federal
24 Controlled Substances Act, and any other drug of the quantitative
25 composition shown in that list for those drugs or which is the same
26 except for containing a lesser quantity of controlled substances;

27 (2) benzphetamine;

1 (3) chlorphentermine;

2 (4) clortermine; and

3 (5) phendimetrazine.

4 (b) Depressants. Any material, compound, mixture, or preparation
5 containing any quantity of the following substances having a depressant effect
6 on the central nervous system:

7 (1) any compound, mixture, or preparation containing:

8 (A) amobarbital;

9 (B) secobarbital; and

10 (C) pentobarbital; or any salt thereof and one or more
11 other active medicinal ingredients which are not listed in any
12 schedule.

13 (2) any of the following drugs, or their salts, in suppository
14 dosage form, approved by the Federal Food and Drug Administration
15 for marketing only as a suppository:

16 (A) amobarbital;

17 (B) secobarbital; and

18 (C) pentobarbital.

19 (3) a substance containing any quantity of a derivative of
20 barbituric acid or any salt of a derivative of barbituric acid;

21 (4) chlorhexadol;

22 (5) embutramide;

23 (6) any drug product containing gamma hydroxybutyric acid,
24 including its salts, isomers, and salts of isomers, for which an
25 application is approved under Section 505 of the Federal Food, Drug,
26 and Cosmetic Act;

1 (7) ketamine, its salts, isomers, and salts of isomers (other
2 names: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone);

3 (8) lysergic acid;

4 (9) lysergic acid amide;

5 (10) methyprylon;

6 (11) perampanel, and its salts, isomers and salts of isomers.

7 (12) sulfondiethylmethane;

8 (13) sulfonethylmethane;

9 (14) sulfonmethane;

10 (15) tiletamine and zolazepam, or any salt thereof (Some trade
11 or other names for a tiletamine-zolazepam combination product:
12 Telazol; (Some trade or other names for tiletamine: 2-(ethylamino)-2-
13 (2-thienyl)-cyclohexanone. Some trade or other names for zolazepam:
14 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-*e*] [1,4]-
15 diazepin-7(1*H*)-one, flupyrazapon);

16 (c) Nalorphine.

17 (d) Narcotic Drugs.

18 (1) Any material, compound, mixture, or preparation
19 containing any of the following narcotic drugs, or their salts calculated
20 as the free anhydrous base or alkaloid, in limited quantities as set forth
21 below:

22 (A) not more than 1.8 grams of codeine per 100
23 milliliters or not more than 90 milligrams per dosage unit, with
24 an equal or greater quantity of an isoquinoline alkaloid of opium;

25 (B) not more than 1.8 grams of codeine per 100
26 milliliters or not more than 90 milligrams per dosage unit, with

1 one or more active, nonnarcotic ingredients in recognized
2 therapeutic amounts;

3 (C) not more than 300 milligrams of dihydrocodeine
4 (hydrocodone) per 100 milliliters or not more than 15 milligrams
5 per dosage unit, with one or more active-nonnarcotic ingredients
6 in recognized therapeutic amounts;

7 (D) not more than 1.8 grams of Dihydrocodeine
8 (hydrocodone) per 100 milliliters or not more than 90 milligrams
9 per dosage unit, with one or more active-nonnarcotic ingredients
10 in recognized therapeutic amounts;

11 (E) not more than 300 milligrams of ethylmorphine per
12 100 milliliters or not more than 15 milligrams per dosage unit,
13 with one or more active, nonnarcotic ingredients in recognized
14 therapeutic amounts;

15 (F) not more than 500 milligrams of opium per 100
16 milliliters or per 100 grams, or not more than 25 milligrams per
17 dosage unit, with one or more active, nonnarcotic ingredients in
18 recognized therapeutic amounts;

19 (G) not more than 50 milligrams of morphine per 100
20 milliliters or per 100 grams with one or more active,
21 nonnarcotic ingredients in recognized therapeutic amounts; and

22 (H) not more than 50 milligrams of morphine per 100
23 milliliters or per 100 grams with one or more active, nonnarcotic
24 ingredients in recognized therapeutic amounts.

25 (2) Any material, compound, mixture, or preparation
26 containing any of the following narcotic drugs or their salts as set below:

27 (A) buprenorphine;

1 (e) Anabolic Steroids. Any drug or hormonal substance chemically
2 and pharmacologically related to testosterone (other than estrogens,
3 progestins, corticosteroids, and dehydroepiandrosterone), and includes:

- 4 (1) $3\beta,17$ -dihydroxy-5 α -androsterane;
- 5 (2) $3\alpha,17\beta$ -dihydroxy-5 α -androsterane;
- 6 (3) 5 α -androsteran-3,17-dione;
- 7 (4) 1-androstenediol ($3\beta,17\beta$ -dihydroxy-5 α -androst-1-ene);
- 8 (5) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy-5 α -androst-1-ene);
- 9 (6) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
- 10 (7) 5-androstenediol ($\beta,17\beta$ -dihydroxy-androst-5-ene);
- 11 (8) 1-androstenedione ([5 α]-androst-1-en-3,17- dione);
- 12 (9) 4-androstenedione (androst-4-en-3,17-dione);
- 13 (10) 5-androstenedione (androst-5-en-3,17-dione);
- 14 (11) bolasterone (7 $\alpha,17\alpha$ - dimethyl-17 β -hydroxyandrost-4-
15 en-3-one);
- 16 (12) boldenone (17 β -hydroxyandrost-1,4- diene-3-one);
- 17 (13) boldione (androsta-1,4-diene-3,17-dione);
- 18 (14) calusterone (7 $\beta,17\alpha$ -dimethyl- β -hydroxyandrost-4-en-3-
19 one);
- 20 (15) clostebol (4-chloro-17 β -hydroxyandrost-4-en-3-one);
- 21 (16) dehydrochloromethyltestosterone (4-chloro-17 β -
22 hydroxy-17 α -methyl- androst-1,4-dien-3-one);
- 23 (17) desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-
24 17 β -ol) (Also known as, "madadol");
- 25 (18) Δ^1 -dihydrotestosterone (Also known as, "1-
26 testosterone") (17 β - hydroxy-5 α -androst-1-en-3-one);

- 1 (19) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
- 2 (20) drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-
- 3 one);
- 4 (21) ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
- 5 (22) fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -
- 6 dihydroxyandrost-4-en-3-one);
- 7 (23) formebolone (2-formyl-17 α -methyl-11 α ,17 β -
- 8 dihydroxyandrost-1,4-dien-3-one);
- 9 (24) furazabol (17 α -methyl-17 β -hydroxyandrostando[2,3-c]-
- 10 furazan);
- 11 (25) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
- 12 (26) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-
- 13 one);
- 14 (27) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-
- 15 en-3-one);
- 16 (28) mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-
- 17 one);
- 18 (29) mesterolone (1 α methyl-17 β -hydroxy-[5 α]-androstan-3-
- 19 one);
- 20 (30) methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-
- 21 dien-3-one);
- 22 (31) methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-
- 23 ene);
- 24 (32) methasterone (2 α ,17 α -dimethyl-5 α -androstan-17 β -ol-3-
- 25 one);

- 1 (33) methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-
2 one);
- 3 (34) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane;
- 4 (35) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane;
- 5 (36) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
- 6 (37) 17 α -methyl-4-hydroxynandrolone(17 α -methyl- 4-
7 hydroxy-17 β -hydroxyestr-4-en-3-one);
- 8 (38) methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-
9 dien-3-one);
- 10 (39) methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-
11 trien-3-one);
- 12 (40) methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-
13 en-3-one);
- 14 (41) mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-
15 one);
- 16 (42) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy- 17 α -
17 methyl-5 α -androst-1-en-3- one) (Also known as, "17- α -methyl-1-
18 testosterone");
- 19 (43) nandrolone (17 β -hydroxyestr-4-en-3-one);
- 20 (44) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
- 21 (45) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
- 22 (46) 19-nor-5-androstenediol (3 β , 17 β -dihydroxyestr-5-ene);
- 23 (47) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
- 24 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-
25 3,17-dione);
- 26 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

- 1 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 2 (51) norbolethone (13 β , 17 α -diethyl-17 β -hydroxygon-4-en-
- 3 3-one);
- 4 (52) norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
- 5 (53) norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-
- 6 one);
- 7 (54) normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-
- 8 one);
- 9 (55) oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-
- 10 androstan-3-one);
- 11 (56) oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-
- 12 en-3-one);
- 13 (57) oxymetholone (17 α -methyl-2-hydroxymethylene-17 β -
- 14 hydroxy-[5 α]-androstan-3-one);
- 15 (58) prostanazol (17 β -hydroxy-5 α androstano[3,2-c]pyrazole);
- 16 (59) stanozolol (17 α -methyl-17 β -hydroxy-[5 α -androst-2-
- 17 eno[3,2-c]-pyrazole);
- 18 (60) stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-
- 19 one);
- 20 (61) testolactone (13-hydroxy-3-oxo-13,17 secoandrosta-1,4-
- 21 dien-17-oic acid lactone);
- 22 (62) testosterone (17 β -hydroxyandrost-4-en-3-one);
- 23 (63) tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-
- 24 4,9,11-trien-3-one);
- 25 (64) trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one); and

1 (65) Any salt, ester, or ether of a drug or substance described
2 or listed in this Subsection (e) of this Section. Except such term does
3 not include an anabolic steroid that is expressly intended for
4 administration through implants to cattle or other nonhuman species
5 and which has been approved by the Secretary of Health and Human
6 Services for such administration. If any person prescribes, dispenses,
7 or distributes such steroid for human use, such person shall be
8 considered to have prescribed, dispensed, or distributed an anabolic
9 steroid within the meaning of this paragraph. DPHSS may exempt by
10 rule a compound, mixture, or preparation containing a stimulant or
11 depressant substance listed in subsections A and B from the application
12 of all or part of this Act, if the compound, mixture, or preparation
13 contains one or more active medicinal ingredients not having a
14 stimulant or depressant effect on the central nervous system and the
15 admixtures are in combinations, quantity, proportion, or concentration
16 that vitiate the potential for abuse of the substances having a stimulant
17 or depressant effect on the central nervous system.

18 (f) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil
19 and encapsulated in a soft gelatin capsule in a U.S. Food and Drug
20 Administration approved product (Some other names for dronabinol: (6a*R*-
21 *trans*)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6*H*-ibenzo[*b,d*]pyran-
22 1-ol]).”

23 **Section 5.** APPENDIX D of Chapter 67, Title 9, Guam Code Annotated, is
24 hereby *amended* to read:

25 “(a) Narcotic drugs. Any material, compound, mixture, or preparation
26 containing any of the following narcotic drugs, or their salts calculated as the
27 free anhydrous base or alkaloid, in limited quantities as set forth below:

1 (1) not more than 1 milligram of difenoxin and not less than
2 25 micrograms of atropine sulfate per dosage unit;

3 (2) dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-
4 diphenyl-3-methyl-2-propionoxybutane); and

5 (3) 2-[(dimethylamino)methyl]-1-(3-
6 methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers
7 and salts of these isomers (including tramadol).

8 (b) Depressants. Any material, compound, mixture, or preparation
9 which contains any quantity of the following substances, including any salts,
10 isomers, and salts of isomers whenever the existence of such salts,
11 isomers, and salts of isomers is possible within the specific chemical
12 designation:

13 (1) alfaxalone;

14 (2) alprazolam;

15 (3) barbital;

16 (4) brexanolone;

17 (5) bromazepam;

18 (6) camazepam;

19 (7) carisoprodol;

20 (8) chloral betaine;

21 (9) chloral hydrate;

22 (10) chlordiazepoxide;

23 (11) clobazam;

24 (12) clonazepam;

25 (13) clorazepate;

26 (14) clotiazepam;

27 (15) cloxazolam;

- 1 (16) delorazepam;
- 2 (17) diazepam;
- 3 (18) dichloraphenazone;
- 4 (19) estazolam;
- 5 (20) ethchlorvynol;
- 6 (21) ethinamate;
- 7 (22) ethyl loflazepate;
- 8 (23) fludiazepam;
- 9 (24) flunitrazepam;
- 10 (25) flurazepam;
- 11 (26) fospropofol;
- 12 (27) halazepam;
- 13 (28) haloxazolam;
- 14 (29) ketazolam;
- 15 (30) lorazepam;
- 16 (31) lorazepam;
- 17 (32) lormetazepam;
- 18 (33) mebutamate;
- 19 (34) medazepam;
- 20 (35) meprobamate;
- 21 (36) methohexital;
- 22 (37) methylphenobarbital (mephobarbital);
- 23 (38) midazolam;
- 24 (39) nimetazepam;
- 25 (40) nitrazepam;
- 26 (41) nordiazepam;
- 27 (42) oxazepam;

- 1 (43) oxazolam;
- 2 (44) petrichloral;
- 3 (45) phenobarbital;
- 4 (46) pinazepam;
- 5 (47) prazepam;
- 6 (48) quazepam;
- 7 (49) suvorexant;
- 8 (50) temazepam;
- 9 (51) tetrazepam;
- 10 (52) triazolam;
- 11 (53) zaleplon;
- 12 (54) zolpidem; and
- 13 (55) zopiclone.

14 (c) Fenfluramine. Any material, compound, mixture, or preparation
15 which contains any quantity of the following substances, including its salts,
16 isomers (whether optical, position, or geometric), and salts of such isomers,
17 whenever the existence of such salts, isomers, and salts of isomers is possible:

- 18 (1) fenfluramine.

19 (d) Lorcaserin. Any material, compound, mixture, or preparation
20 which contains any quantity of the following substances, including its salts
21 isomers and salts of such isomers, whenever the existence of such salts,
22 isomers, and salts of isomers is possible:

- 23 (1) lorcaserin.

24 (e) Stimulants. Any material, compound, mixture, or preparation
25 containing any quantity of the following substances having a stimulant effect
26 on the central nervous system, including their salts, isomers, and salts of
27 isomers:

- 1 (1) cathine ((+)-norpseudoephedrine);
- 2 (2) diethylpropion;
- 3 (3) fencamfamin;
- 4 (4) fenproporex;
- 5 (5) mazindol;
- 6 (6) mefenorex;
- 7 (7) modafinil;
- 8 (8) pemoline (including organometallic complexes and
- 9 chelates thereof);
- 10 (9) phentermine;
- 11 (10) pipradrol;
- 12 (11) sibutramine;
- 13 (12) solriamfetol (2-amino-3-phenylpropyl carbamate;
- 14 benzenepropanol, beta-amino-carbamate (ester)); and
- 15 (13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

16 (f) Other substances. Any material, compound, mixture, or
17 preparation containing any quantity of the following substance, including its
18 salts:

- 19 (1) pentazocine;
- 20 (2) butorphanol (including its optical isomers); and
- 21 (3) eluxadoline (5-[[[(2*S*)-2-amino-3-[4-aminocarbonyl]-2,6-
- 22 dimethylphenyl]-1-oxopropyl]][(1*S*)-1-4-phenyl-1*H*-imidazol-2-
- 23 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) including its optical
- 24 isomers and salts of isomers.

25 (g) DPHSS may exempt by rule any compound, mixture, or
26 preparation containing a depressant substance listed in subsection B from the
27 application of all or part of this Act, if the compound, mixture, or preparation

1 contains one or more active medicinal ingredients not having a depressant
2 effect on the central nervous system and the admixtures are in combinations,
3 quantity, proportion, or concentration that vitiate the potential for abuse of the
4 substances having a depressant effect on the central nervous system.”

5 **Section 6.** APPENDIX E of Chapter 67, Title 9, Guam Code Annotated, is
6 hereby *amended* to read:

7 “(a) Narcotic drugs. Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or preparation containing
9 any of the following narcotic drugs and their salts, as set forth below:

10 (b) Narcotic drugs containing non-narcotic active medicinal
11 ingredients. Any compound, mixture, or preparation containing any of the
12 following narcotic drugs, or their salts calculated as the free anhydrous base
13 or alkaloid, in limited quantities as set forth below, which shall include one or
14 more non-narcotic active medicinal ingredients in sufficient proportion to
15 confer upon the compound, mixture, or preparation, valuable medicinal
16 qualities other than those possessed by the narcotic drug alone:

17 (1) not more than 200 milligrams of codeine per 100
18 milliliters or per 100 grams;

19 (2) not more than 100 milligrams of dihydrocodeine per 100
20 milliliters or per 100 grams;

21 (3) not more than 100 milligrams of ethylmorphine per 100
22 milliliters or per 100 grams;

23 (4) not more than 2.5 milligrams of diphenoxylate and not less
24 than 25 micrograms of atropine sulfate per dosage unit;

25 (5) not more than 100 milligrams of opium per 100
26 milliliters or per 100 grams; and

1 (6) not more than 0.5 milligram of difenoxin and not less
2 than 25 micrograms of atropine sulfate per dosage unit.

3 (c) Stimulants. Any material, compound, mixture, or preparation
4 containing any quantity of the following substances having a stimulant effect
5 on the central nervous system, including their salts, isomers and salts of
6 isomers:

7 (1) pyrovalerone.

8 (d) Depressants. Any material, compound, mixture, or preparation
9 which contains any quantity of the following substances having a depressant
10 effect on the central nervous system, including its salts:

11 (1) brivaracetam ((S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-
12 yl]butanamide) (also referred to as BRV; UCB-34714; Briviact)
13 including its salts;

14 (2) cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-
15 yl)ethyl]carbamate; 2*H*-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-,
16 carbamate(ester), (alpha*R*)-; carbamic acid (*R*)-(+)-1-(2-
17 chlorophenyl)-2-(2*H*-tetrazol-2-yl)ethyl ester);

18 (3) ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-
19 phenyl]-carbamic acid ethyl ester];

20 (4) lacosamide [(*R*)-2-acetoamido-*N*-benzyl-3-methoxy-
21 propionamide];

22 (5) lasmiditan [2,4,6-trifluoro-*N*-(6-(1-methylpiperidine-4-
23 carbonyl)pyridine-2-yl)-benzamide]; and

24 (6) pregabalin [(*S*)-3-(aminomethyl)-5-methylhexanoic
25 acid].”

26 **Section 7. Severability.** If any provision of this Act or its application to any
27 person or circumstance is held invalid, the invalidity does not affect other provisions

1 or applications of this Act that can be given effect without the invalid provision or
2 application, and to this end the provisions of this Act are severable.

LOURDES A. LEON GUERRERO
GOVERNOR



JOSHUA F. TENORIO
LT. GOVERNOR

UFISINAN I MAGA'HĀGAN GUĀHAN
OFFICE OF THE GOVERNOR OF GUAM

April 11, 2022

Doc Type: 36GL-22-1903
OFFICE OF THE SPEAKER
THERESE M. TERLAJE

HONORABLE THERESE M. TERLAJE, *Speaker*
I Mina'trentai Sais Na Liheslaturan Guåhan
36th Guam Legislature
Guam Congress Building
163 Chalan Santo Papa
Hagåtña, Guam 96910

04-12-2022


Time: 11:31a.m.
Received: [Signature]

Re: **BILL NO. 169-36 (LS) – AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E, ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT**

Hafa Adai Madame Speaker,


The number of new illegal synthetic drugs being produced is constantly increasing. Development of new drugs is the criminal's method of attempting to avoid prosecution, by creating a chemical compound that is not currently prohibited by the Controlled Substances Act. As new dangerous drugs are developed, law enforcement must be able to protect the citizens of Guam from the individuals who produce, transport, and sell them. Prosecution of individuals involved in the distribution chain of new drugs is only possible if the Controlled Substances Act is kept up to date by identifying new drugs and including them in the schedules of compounds that are illegal to produce, sell, or possess in Guam. Bill 169-36 accomplishes this by updating the appendices of the Guam Uniform Controlled Substances Act. I hereby sign Bill No.169-36 into law as **Public Law No. 36-89**.

Senseremente,


LOURDES A. LEON GUERRERO
Maga'hågan Guåhan
Governor of Guam

COMMITTEE ON RULES
RECEIVED:

April 13, 2022
9:46 A.M.




Enclosure: Bill No. 169-36 (LS) *nka P.L. No. 36-89*

cc via email: *Honorable* Joshua F. Tenorio, *Sigundo Maga'låhen Guåhan*
Compiler of Laws

I MINA'TRENTAI SAIS NA LIHESLATURAN GUÅHAN
2022 (SECOND) Regular Session

CERTIFICATION OF PASSAGE OF AN ACT TO *I MAGA'HÅGAN GUÅHAN*

This is to certify that **Bill No. 169-36 (LS)**, “**AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E, ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT,**” was on the 1st day of April 2022, duly and regularly passed.




Therese M. Terlaje
Speaker

Attested:



Amanda L. Shelton
Legislative Secretary

This Act was received by *I Maga'hågan Guåhan* this 1 day of April,
2022, at 9:39 o'clock P.M.



Assistant Staff Officer
Maga'håga's Office

APPROVED:



Lourdes A. Leon Guerrero
I Maga'hågan Guåhan

Date: 4/11/2022

Public Law No. 36-89

2022-16197
RCUD AT CENTRAL FILES
APR 4 '22 AM 9:01

Elaine Tajalle

I MINA'TRENTAI SAIS NA LIHESLATURAN GUÅHAN
2021 (FIRST) Regular Session

Bill No. 169-36 (LS)

As amended by the Committee on Health,
Land, Justice, and Culture.

Introduced by:

Telena Cruz Nelson
V. Anthony Ada
Frank Blas Jr.
Joanne Brown
Christopher M. Dueñas
James C. Moylan
Tina Rose Muña Barnes
Sabina Flores Perez
Clynton E. Ridgell
Joe S. San Agustin
Amanda L. Shelton
Telo T. Taitague
Jose “Pedo” Terlaje
Therese M. Terlaje
Mary Camacho Torres

**AN ACT TO *AMEND* APPENDIX A, APPENDIX B,
APPENDIX C, APPENDIX D, AND APPENDIX E, ALL OF
CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED,
RELATIVE TO UPDATING THE LIST OF SCHEDULED
CONTROLLED SUBSTANCES PROVIDED IN THE
GUAM UNIFORM CONTROLLED SUBSTANCES ACT.**

1 **BE IT ENACTED BY THE PEOPLE OF GUAM:**

2 **Section 1. Legislative Findings and Intent.** *I Liheslaturan Guåhan* finds
3 that the continued health and public safety of the people of Guam necessitates a
4 unified legal framework that regulates the use, dispensation, and categorization of

1 controlled substances. The purpose of this Act is to update Schedule I through
2 Schedule V of controlled substances based on their medical utility and potential for
3 dependence or abuse.

4 *I Liheslaturan Guåhan* further finds that the Department of Public Health and
5 Social Services (DPHSS) has the authority to administer this Act and to add, delete,
6 or otherwise update Appendices A, B, C, D, and E in accordance with § 67.201 of
7 Chapter 67, Title 9, Guam Code Annotated. The following updated lists of controlled
8 substances are in accordance with DPHSS's findings and research.

9 It is, therefore, the intent of *I Liheslaturan Guåhan* and DPHSS to properly
10 update the list of scheduled drugs to reflect federal regulations provided in §1308.11,
11 §1308.12, §1308.13, §1308.14, and §1308.15 of Title 21, U.S. Code of Federal
12 Regulations, relative to schedules of controlled substances.

13 **Section 2.** APPENDIX A of Chapter 67, Title 9, Guam Code Annotated, is
14 hereby *amended* to read:

15 “(a) Opiates. Any of the following opiates, including their isomers,
16 esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the
17 existence of such isomers, esters, ethers and salts is possible within the
18 specific chemical designation (for purposes of 3-methylthiofentanyl only, the
19 term isomer includes the optical and geometric isomers):

20 (1) acetyl-alpha-methylfentanyl (*N*-[1-(1-methyl-2-
21 phenethyl)-4-piperidinyl]-*N*-phenylacetamide);

22 (2) acetylmethadol;

23 (3) acetyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
24 phenylacetamide);

25 (4) acryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
26 phenylacrylamide; also known as: acryloylfentanyl);

- 1 (5) AH-7921 (3,4-dichloro-*N*-[(1-dimethylamino)
- 2 cyclohexylmethyl]benzamide);
- 3 (6) allylprodine;
- 4 (7) alphacetylmethadol (except levoalphacetylmethadol also
- 5 known as levo-alpha-acetylmethadol, levomethadyl acetate, or
- 6 LAAM);
- 7 (8) alphameprodine;
- 8 (9) alphamethadol;
- 9 (10) alpha-methylfentanyl (*N*-[1-(alpha-methyl-beta-phenyl)
- 10 ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(*N*-
- 11 propanilido) piperidine);
- 12 (11) alpha-methylthiofentanyl (*N*-[1-methyl-2-(2-
- 13 thienyl)ethyl-4-piperidinyl]-*N*-phenylpropanamide);
- 14 (12) benzethidine;
- 15 (13) betacetylmethadol;
- 16 (14) beta-hydroxyfentanyl (*N*-[1-(2-hydroxy-2-phenethyl)-4-
- 17 piperidinyl]-*N*-phenylpropamide);
- 18 (15) beta-hydroxy-3-methylfentanyl (*N*-[1-(2-hydroxy-2-
- 19 phenethyl)-3-methyl-4-piperidinyl]-*N*-phenylpropanamide);
- 20 (16) *beta*-Hydroxythiofentanyl *N*-[1-[2-hydroxy-2-(thiophen-
- 21 2-yl)ethyl]piperidin-4-yl]-*N*-phenylpropionamide ;
- 22 (17) betameprodine;
- 23 (18) betamethadol;
- 24 (19) betaprodine;
- 25 (20) butyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
- 26 phenylbutyramide);
- 27 (21) clonitazene;

- 1 (22) cyclopropyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
2 phenylcyclopropanecarboxamide);
3 (23) dextromoramide;
4 (24) diampromide;
5 (25) diethylthiambutene;
6 (26) difenoxin;
7 (27) dimenoxadol;
8 (28) dimepheptanol;
9 (29) dimethylthiambutene;
10 (30) dioxaphetyl butyrate;
11 (31) dipipanone;
12 (32) ethylmethylthiambutene;
13 (33) etonitazene;
14 (34) etoxeridine;
15 (35) 4-Fluoroisobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-
16 phenethylpiperidin-4-yl)isobutyramide; also known as: *para*-
17 fluoroisobutyryl fentanyl);
18 (36) furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-
19 phenylfuran-2-carboxamide);
20 (37) furethidine;
21 (38) hydroxypethidine;
22 (39) ketobemidone;
23 (40) levomoramide;
24 (41) levophenacylmorphane;
25 (42) methoxyacetyl fentanyl (2-methoxy-*N*-(1-
26 phenethylpiperidin-4-yl)-*N*-phenylacetamide);

- 1 (43) 3-methylfentanyl (*N*-[3-methyl-1-(2-phenylethyl)-4-
2 piperidyl]-*N*-phenylpropanamide);
- 3 (44) 3-methylthiofentanyl (*N*-[3-methyl-1-(2- thienylethyl)-4-
4 piperidiny]-*N*-phenylpropanamide);
- 5 (45) morpheridine;
- 6 (46) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 7 (47) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl) piperazine);
- 8 (48) noracymethadol;
- 9 (49) norlevorphanol;
- 10 (50) normethadone;
- 11 (51) norpipanone;
- 12 (52) ocfentanil (*N*-(2-fluorophenyl)-2-methoxy-*N*-(1-
13 phenethylpiperidin-4-yl)acetamide);
- 14 (53) *ortho*-Fluorofentanyl (*N*-(2-fluorophenyl)-*N*-(1-
15 phenethylpiperidin-4-yl)propionamide); also known as: 2-
16 fluorofentanyl;
- 17 (54) *para*-Fluorobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-
18 phenethylpiperidin-4-yl)butyramide);
- 19 (55) *para*-fluorofentanyl (*N*-(4-fluorophenyl)-*N*-[1-(2-
20 phenethyl)-4-piperidiny]-propanamide);
- 21 (56) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 22 (57) phenadoxone;
- 23 (58) phenampromide;
- 24 (59) phenomorphan;
- 25 (60) phenoperidine;
- 26 (61) piritramide;
- 27 (62) proheptazine;

- 1 (63) properidine;
2 (64) propiram;
3 (65) racemoramide;
4 (66) tetrahydrofuranlyl fentanyl (*N*-(1-phenethylpiperidin-4-
5 yl)-*N*-phenyltetrahydrofuran-2-carboxamide);
6 (67) thiofentanyl (*N*-phenyl-*N*-[1-(2-thienyl)ethyl-4-
7 piperidinyll]-propanamide);
8 (68) tilidine;
9 (69) trimeperidine; and
10 (70) U-47700(3,4-Dichloro-*N*-[2-
11 (dimethylamino)cyclohexyl]-*N*-methylbenzamide).

12 (b) Opium derivatives. Any of the following opium derivatives, its
13 salts, isomers and salts of isomers whenever the existence of such salts,
14 isomers, and salts of isomers is possible within the specific chemical
15 designation:

- 16 (1) acetorphine;
17 (2) acetyldihydrocodeine;
18 (3) benzylmorphine;
19 (4) codeine methylbromide;
20 (5) codeine-*N*-Oxide;
21 (6) cyprenorphine;
22 (7) desomorphine;
23 (8) dihydromorphine;
24 (9) drotebanol;
25 (10) etorphine (except hydrochloride salt);
26 (11) heroin;
27 (12) hydromorphenol;

- 1 (13) methyldesorphine;
- 2 (14) methyldihydromorphine;
- 3 (15) morphine methylbromide;
- 4 (16) morphine methylsulfonate;
- 5 (17) morphine-N-oxide;
- 6 (18) myrophine;
- 7 (19) nicocodeine;
- 8 (20) nicomorphine;
- 9 (21) normorphine;
- 10 (22) pholcodine; and
- 11 (23) thebacon.

12 (c) Hallucinogenic substances. Any material, compound, mixture, or
13 preparation which contains any quantity of the following hallucinogenic
14 substances, or which contains any of its salts, isomers, and salts of isomers
15 whenever the existence of such salts, isomers, and salts of isomers is possible
16 within the specific chemical designation (for purposes of this paragraph only,
17 the term "isomer" includes the optical, position and geometric isomers):

18 (1) Alpha-ethyltryptamine (some trade or other names:
19 etryptamine; Monase; α -ethyl-1H-indole-3-ethanamine; 3-(2-
20 aminobutyl) indole; α -ET; and AET);

21 (2) 4-bromo-2,5-dimethoxy-amphetamine (some trade or
22 other names: 4-bromo-2,5-dimethoxy- α -methylphenethylamine;
23 4-bromo-2,5-DMA);

24 (3) 4-Bromo-2,5-dimethoxyphenethylamine (some trade or
25 other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-
26 desmethyl DOB; 2C-B, Nexus);

- 1 (4) 2,5-dimethoxyamphetamine (some trade or other names:
2 2,5-dimethoxy- α -methylphenethylamine; 2,5-DMA);
- 3 (5) 2,5-dimethoxy-4-ethylamphet-amine (some trade or other
4 name: DOET);
- 5 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other
6 name: 2C-T-7);
- 7 (7) 4-methoxyamphetamine (some trade or other names: 4-
8 methoxy- α -methylphenethylamine; paramethoxyamphetamine, PMA);
- 9 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 10 (9) 4-methyl-2,5-dimethoxy-amphetamine (some trade or
11 other names: 4-methyl-2,5-dimethoxy- α -methylphenethylamine;
12 “DOM”; and “STP”);
- 13 (10) 3,4-methylenedioxy amphetamine;
- 14 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 15 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known
16 as: N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-
17 ethyl MDA, MDE, MDEA);
- 18 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also
19 known as: N-hydroxy-alpha-methyl-3,4(methylenedioxy)-
20 phenethylamine, and N-hydroxy MDA);
- 21 (14) 3,4,5-trimethoxy amphetamine;
- 22 (15) 5-methoxy-N,N-dimethyltryptamine (some trade or other
23 names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT;
- 24 (16) Alpha-methyltryptamine (other name: AMT);
- 25 (17) bufotenine (some trade or other names: 3-(β -
26 Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-

1 indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;
2 mappine);

3 (18) diethyltryptamine (some trade or other names: N,N-
4 Diethyltryptamine; DET);

5 (19) dimethyltryptamine (some trade or other name: DMT);

6 (20) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-
7 MeO-DIPT);

8 (21) ibogaine (some trade or other names: 7-Ethyl-
9 6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido
10 [1',2':1,2] azepino [5,4-b] indole; Tabernanthe iboga);

11 (22) lysergic acid diethylamide;

12 (23) [Repealed];

13 (24) mescaline;

14 (25) parahexyl-7374(some trade or other names: 3-Hexyl-1-
15 hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
16 Synhexyl);

17 (26) peyote (meaning all parts of the plant presently classified
18 botanically as *Lophophora williamsii* Lemaire, whether growing or not,
19 the seeds thereof, any extract from any part of such plant, and every
20 compound, manufacture, salts, derivative, mixture, or preparation of
21 such plant, its seeds or extracts);

22 (27) N-ethyl-3-piperidyl benzilate;

23 (28) N-methyl-3-piperidyl benzilate;

24 (29) psilocybin;

25 (30) psilocyn;

26 (31) [Repealed];

1 (32) ethylamine analog of phencyclidine (some trade or other
2 names: N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)
3 ethylamine, N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE);

4 (33) pyrrolidine analog of phencyclidine (some trade or other
5 names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);

6 (34) thiophene analog of phencyclidine (some trade or other
7 names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienyl analog of
8 phencyclidine, TPCP, TCP);

9 (35) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (some other
10 names: TCPy)

11 (36) 4-methylmethcathinone (Mephedrone);

12 (37) 3,4-methylenedioxypropylvalerone (MDPV);

13 (38) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E);

14 (39) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D);

15 (40) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C);

16 (41) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I);

17 (42) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl] ethanamine (2C-
18 T-2);

19 (43) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine
20 (2C-T-4);

21 (44) 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H);

22 (45) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N);

23 (46) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-
24 P);

25 (47) 3,4-Methylenedioxy-N-methylcathinone (Methylone);

26 (48) (1-pentyl-1*H*-indol-3-yl) (2,2,3,3-
27 tetramethylcyclopropyl) methanone (UR-144);

- 1 (49) [1-(5-fluoro-pentyl)-1*H*-indol-3-yl](2,2,3,3-
2 tetramethylcyclopropyl) methanone (5-fluoro-UR-144, XLR11);
3 (50) *N*-(1-adamantyl)-1-pentyl-1*H*-indazole-3-carboxamide
4 (APINACA, AKB48);
5 (51) quinolin-8-yl 1-pentyl-1*H*-indole-3-carboxylate (PB-22;
6 QUPIC);
7 (52) quinolin-8-yl 1-(5-fluoropentyl)-1*H*-indole-3-carboxylate
8 (5-fluoro-PB-22; 5F-PB-22);
9 (53) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
10 fluorobenzyl)-1*H*-indazole-3-carboxamide (AB-FUBINACA);
11 (54) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-
12 indazole-3-carboxamide (ADB-PINACA);
13 (55) 2-(4-iodo-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
14 ethanamine (25I-NBOMe, 2C-I-NBOMe);
15 (56) 2-(4-chloro-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
16 ethanamine (25C-NBOMe, 2C-C-NBOMe);
17 (57) 2-(4-bromo-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)
18 ethanamine (25B-NBOMe, 2C-B-NBOMe);
19 (58) 4-methyl-*N*-ethylcathinone (4-MEC);
20 (59) 4-methyl-*alpha*-pyrrolidinopropiophenone(4-MePPP);
21 (60) *alpha*-pyrrolidinopentiophenone (α -PVP);
22 (61) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
23 (butylone, bk-MBDB);
24 (62) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
25 (63) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one
26 (pentylone, bk-MBDB);
27 (64) 4-fluoro-*N*-methylcathinone (4-FMC; flephedrone);

- 1 (65) 3-fluoro-*N*-methylcathinone (3-FMC);
- 2 (66) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one
3 (naphyrone);
- 4 (67) alpha-pyrrolidinobutiophenone (α -PBP);
- 5 (68) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
6 (cyclohexylmethyl)-1*H*-indazole-3-carboxamide (AB-CHMINACA);
- 7 (69) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1*H*-
8 indazole-3-carboxamide (AB-PINACA);
- 9 (70) [1-(5-fluoropentyl)-1*H*-indazol-3-yl](naphthalen-1-
10 yl)methanone (THJ-2201);
- 11 (71) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
12 (cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-
13 CHMINACA; ADB- CHMINACA);
- 14 (72) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-
15 carboxamido)-3,3-dimethylbutanoate (Other names: 5F-ADB; 5F-
16 MDMB-PINACA);
- 17 (73) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-
18 carboxamido)-3-methylbutanoate (Other names: 5F-AMB);
- 19 (74) *N*-(adamantan-1-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-
20 carboxamide (Other names: 5F-APINACA, 5F-AKB48);
- 21 (75) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-
22 fluorobenzyl)-1*H*-indazole-3-carboxamide (Other names: ADB-
23 FUBINACA);
- 24 (76) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-
25 carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-
26 CHMICA, MMB-CHMINACA);

1 (77) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-
2 carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-
3 FUBINACA); and

4 (78) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-
5 carboxamido)-3-methylbutanoate, (FUB-AMB, MMB-FUBINACA,
6 AMB-FUBINACA).

7 (d) *Depressants*. Any material, compound, mixture or preparation
8 which contains any quantity of the following substances having a depressant
9 effect on the central nervous system, including its salts, isomers and salts of
10 isomers whenever the existence of such salts, isomers, and salts of isomers is
11 possible within the specific chemical designation:

12 (1) gamma-hydroxybutyric acid (some other names include
13 GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-
14 hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

15 (2) mecloqualone; and

16 (3) methaqualone.

17 (e) *Stimulants*. Any material, compound, mixture, or preparation
18 which contains any quantity of the following substances having a stimulant
19 effect on the central nervous system, including its salts, isomers and salts of
20 isomers:

21 (1) Aminorex (other names: aminoxaphen; 2-amino-5-
22 phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine);

23 (2) N-Benzylpiperazine (other names: BZP, 1-
24 benzylpiperazine);

25 (3) Cathinone (other names: 2-amino-1-phenyl-1-
26 propanone; alpha-aminopropiophenone; 2-aminopropiophenone; and
27 norephedrone);

1 (4) Fenethylamine;

2 (5) Methcathinone (other names: 2-(methylamino)-
3 propiophenone; alpha-(methylamino)propiophenone; 2-
4 (methylamino)-1-phenylpropan-1-one; alpha-*N*-
5 methylaminopropiophenone; monomethylpropion; ephedrone; *N*-
6 methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and
7 UR1432), its salts, optical isomers and salts of optical isomers);

8 (6) (\pm)*cis*-4-methylaminorex (other name: (\pm)*cis*-4,5-
9 dihydro-4-methyl-5-phenyl-2-oxazoline);

10 (7) *N*-ethylamphetamine; and

11 (8) *N,N*-dimethylamphetamine (also known as *N,N*-alpha-
12 trimethyl-benzeneethanamine; *N,N*-alpha-trimethylphenethylamine).

13 (f) *Cannabimimetic agents*. Any material, compound, mixture or
14 preparation which contains any quantity of the following substances or which
15 contains their salts, isomers, and salts of isomers whenever the existence of
16 such salts, isomers, and salts of isomers is possible within the specific
17 chemical designation:

18 (1) 5-(1,1-dimethylheptyl)-2-[(1*R*,3*S*)-3-
19 hydroxycyclohexyl]-phenol CP-47,497);

20 (2) 5-(1,1-dimethyloctyl)-2-[(1*R*,3*S*)-3-hydroxycyclohexyl]-
21 phenol, (cannabicyclohexanol or CP-47,497 C8-homolog);

22 (3) 1-Butyl-3-(1-naphthoyl)indole, its optical, positional, and
23 geometric isomers, salts and salts of isomers (other names: JWH-073);

24 (4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole, its
25 optical, positional, and geometric isomers, salts and salts of isomers
26 (other names: JWH-200);

1 (5) 1-Pentyl-3-(1-naphthoyl)indole, its optical, positional, and
2 geometric isomers, salts and salts of isomers (other names: JWH-018
3 and AM678);

4 (6) *Salvia divinorum* or *Salvinorum A*; all parts of the plant
5 presently classified botanically as *Salvia divinorum*, whether growing
6 or not, the seeds thereof, any extract from any part of such plant, and
7 every compound, manufacture, salts, derivative, mixture, or
8 preparation of such plant, its seeds or extracts;

9 (7) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);

10 (8) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);

11 (9) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);

12 (10) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

13 (11) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

14 (12) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);

15 (13) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);

16 (14) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and
17 RCS-4);

18 (15) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole
19 7008(SR-18 and RCS-8);

20 (16) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); and

21 (17) any synthetic cannabinoid.

22 (g) Temporary listing of substances subject to emergency
23 scheduling. Any material, compound, mixture or preparation which contains
24 any quantity of the following substances:

25 (1) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide, its
26 isomers, esters, ethers, salts and salts of isomers, esters and ethers (other
27 name: valeryl fentanyl);

1 (2) *N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-
2 yl)butyramide, its isomers, esters, ethers, salts and salts of isomers,
3 esters and ethers (other name: *para*-methoxybutyryl fentanyl);

4 (3) *N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-
5 yl)isobutyramide, its isomers, esters, ethers, salts and salts of isomers,
6 esters and ethers (other name: *para*-chloroisobutyryl fentanyl);

7 (4) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide,
8 its isomers, esters, ethers, salts and salts of isomers, esters and ethers
9 (other name: isobutyryl fentanyl);

10 (5) *N*-(1-phenethylpiperidin-4-yl)-*N*-
11 phenylcyclopentanecarboxamide, its isomers, esters, ethers, salts and
12 salts of isomers, esters and ethers (other name: cyclopentyl fentanyl);

13 (6) Naphthalen-1-yl 1-(5-fluoropentyl)-1*H*-indole-3-
14 carboxylate, its optical, positional, and geometric isomers, salts and
15 salts of isomers (other names: NM2201; CBL2201);

16 (7) *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
17 fluoropentyl)-1*H*-indazole-3-carboxamide, its optical, positional, and
18 geometric isomers, salts and salts of isomers (other names: 5F-AB-
19 PINACA);

20 (8) 1-(4-cyanobutyl)-*N*-(2-phenylpropan-2-yl)-1*H*-indazole-
21 3-carboximide, its optical, positional, and geometric isomers, salts and
22 salts of isomers (other names: 4-CN-CUMYL-BUTINACA; 4-cyano-
23 CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-
24 BINACA; SGT-78);

25 (9) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-
26 carboxamido)-3-methylbutanoate, its optical, positional, and

1 geometric isomers, salts and salts of isomers (other names: MMB-
2 CHMICA, AMB- CHMICA);

3 (10) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-
4 pyrrolo[2,3-*b*]pyridine-3-carboxamide, its optical, positional, and
5 geometric isomers, salts and salts of isomers (other names: 5F-
6 CUMYL- P7AICA);

7 (11) *N*-Ethylpentylone, its optical, positional, and geometric
8 isomers, salts and salts of isomers (other names: ephylone, 1-(1,3-
9 benzodioxol-5-yl)- 2-(ethylamino)-pentan-1-one);

10 (12) ethyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-
11 3,3-dimethylbutanoate, its optical, positional, and geometric isomers,
12 salts and salts of isomers (trivial name: 5F-EDMB-PINACA);

13 (13) methyl 2-(1-(5-fluoropentyl)-1*H*-indole-3-carboxamido)-
14 3,3-dimethylbutanoate, its optical, positional, and geometric isomers,
15 salts and salts of isomers (trivial name: 5F-MDMB-PICA);

16 (14) *N*-(adamantan-1-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-
17 carboxamide, its optical, positional, and geometric isomers, salts and
18 salts of isomers (trivial names: FUB-AKB48; FUB-APINACA; AKB48
19 *N*-(4-FLUOROBENZYL));

20 (15) 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-
21 indazole-3-carboxamide, its optical, positional, and geometric isomers,
22 salts and salts of isomers (trivial names: 5F-CUMYL-PINACA; SGT-
23 25);

24 (16) (1-(4-fluorobenzyl)-1*H*-indol-3-yl)(2,2,3,3-
25 tetramethylcyclopropyl) methanone, its optical, positional, and
26 geometric isomers, salts and salts of isomers (trivial name: FUB-144);

1 (17) *N*-Ethylhexedrone, its optical, positional, and geometric
2 isomers, salts and salts of isomers (Other name: 2-(ethylamino)-1-
3 phenylhexan-1-one;

4 (18) *alpha*-Pyrrolidinohexanophenone, its optical, positional,
5 and geometric isomers, salts and salts of isomers (Other names: α -PHP;
6 *alpha*-pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidine-1-yl)hexan-
7 1-one);

8 (19) 4-Methyl-*alpha*-ethylaminopentiophenone, its optical,
9 positional, and geometric isomers, salts and salts of isomers (Other
10 names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);

11 (20) 4-Methyl-*alpha*-pyrrolidinohexiophenone, its
12 optical, positional, and geometric isomers, salts and salts of
13 isomers (Other names: MPHP; 4-methyl-*alpha*-
14 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidine-1-
15 yl)hexan-1-one);

16 (21) *alpha*-Pyrrolidinoheptaphenone, its optical, positional,
17 and geometric isomers, salts and salts of isomers (Other names: PV8;
18 1-phenyl-2-(pyrrolidine-1-yl)heptan-1-one); and

19 (22) 4'-Chloro-*alpha*-pyrrolidinovalerophenone, its optical,
20 positional, and geometric isomers, salts and salts of isomers (Other
21 names: 4-chloro- α -PVP; 4'-chloro-*alpha*-pyrrolidinopentiophenone; 1-
22 (4-chlorophenyl)-2-(pyrrolidine-1-yl)pentan-1-one).”

23 **Section 3.** APPENDIX B of Chapter 67, Title 9, Guam Code Annotated, is
24 hereby *amended* to read:

25 “(a) Substances, vegetable origin or chemical synthesis. Any of the
26 following substances whether produced directly or indirectly by extraction

1 from substances of vegetable origin, or independently by means of chemical
2 synthesis, or by a combination of extraction and chemical synthesis:

3 (1) Opium and opiate, and any salt, compound, derivative, or
4 preparation of opium or opiate excluding apomorphine, thebaine-
5 derived butorphanol, dextrorphan, nalbuphine, naldemedine,
6 nalmeffene, naloxegol, naloxone, 6 β -naltrexol and naltrexone, and their
7 respective salts, but including the following:

- 8 (A) codeine;
- 9 (B) dihydroetorphine;
- 10 (C) ethylmorphine;
- 11 (D) etorphine hydrochloride;
- 12 (E) granulated opium;
- 13 (F) hydrocodone;
- 14 (G) hydromorphone;
- 15 (H) metopon;
- 16 (I) morphine;
- 17 (J) noroxymorphone;
- 18 (K) opium extracts;
- 19 (L) opium fluid;
- 20 (M) oripavine;
- 21 (N) oxycodone;
- 22 (O) oxymorphone;
- 23 (P) powdered opium;
- 24 (Q) raw opium;
- 25 (R) thebaine; and
- 26 (S) tincture of opium.

1 (2) Any salt, compound, derivative, or preparation thereof
2 which is chemically equivalent or identical with any of the substances
3 listed in Subsection (a)(1) of this Section, except that these substances
4 shall not include the isoquinoline alkaloids of opium;

5 (3) Opium poppy and poppy straw;

6 (4) Coca leaves and any salt, compound, derivative, or
7 preparation of coca leaves, (including cocaine and ecgonine and their
8 salts, isomers, derivatives, and salts of isomers and derivatives), and
9 any salt, compound, derivative, or preparation thereof which is
10 chemically equivalent or identical with any of these substances, except
11 that the substances shall not include:

12 (A) decocainized coca leaves or extraction of coca
13 leaves, which extractions do not contain cocaine or ecgonine; or

14 (B) ioflupane.

15 (5) Concentrate of poppy straw (the crude extract of poppy
16 straw in either liquid, solid, or powder form which contains the
17 phenanthrene alkaloids of the opium poppy).

18 (b) Opiates. Any of the following opiates, including its isomers,
19 esters, ethers, salts, and salts of isomers, esters, and ethers whenever the
20 existence of such isomers, esters, ethers, and salts is possible within the
21 specific chemical designation, dextrorphan and levopropoxyphene excepted:

22 (1) alfentanil;

23 (2) alphaprodine;

24 (3) anileridine;

25 (4) bezitramide;

26 (5) bulk dextropropoxyphene (non-dosage forms);

27 (6) carfentanil;

- 1 (7) dihydrocodeine;
- 2 (8) diphenoxylate;
- 3 (9) fentanyl;
- 4 (10) isomethadone;
- 5 (11) levo-alpha-acetylmethadol [some other names: levo-alpha-
- 6 acetylmethadol, levomethadyl acetate, LAAM];
- 7 (12) levomethorphan;
- 8 (13) levorphanol;
- 9 (14) metazocine;
- 10 (15) methadone;
- 11 (16) methadone-intermediate, 4-cyano-2-dimethylamino-4,4-
- 12 diphenyl butane;
- 13 (17) moramide-intermediate, 2-methyl-3-morpholino-1, 1-
- 14 diphenylpropane-carboxylic acid;
- 15 (18) pethidine (meperidine);
- 16 (19) pethidine-intermediate-A, 4-cyano-1-methyl-4-
- 17 phenylpiperidine;
- 18 (20) pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-
- 19 carboxylate;
- 20 (21) pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-
- 21 4-carboxylic acid;
- 22 (22) phenazocine;
- 23 (23) piminodine;
- 24 (24) racemethorphan;
- 25 (25) racemorphan;
- 26 (26) remifentanil;
- 27 (27) sufentanil;

1 (28) tapentadol; and

2 (29) thiafentanil.

3 (c) Stimulants. Any material, compound, mixture, or preparation
4 which contains any quantity of the following substances having a stimulant
5 effect on the central nervous system:

6 (1) amphetamine, its salts, optical isomers, and salts of its
7 optical isomers;

8 (2) methamphetamine, its salts, isomers, and salts of its
9 isomers;

10 (3) phenmetrazine and its salts;

11 (4) methylphenidate; and

12 (5) lisdexamfetamine, its salts, isomers, and salts of its
13 isomers.

14 (d) Depressants. Any material, compound, mixture, or preparation
15 which contains any quantity of the following substances having a depressant
16 effect on the central nervous system, including its salts, isomers, and salts of
17 isomers whenever the existence of such salts, isomers, and salts of isomers is
18 possible within the specific chemical designation:

19 (1) amobarbital;

20 (2) pentobarbital;

21 (3) phencyclidine;

22 (4) secobarbital; and

23 (5) glutethimide;

24 (e) Hallucinogenic substances.

25 (1) Nabilone (other name for nabilone: (±)-trans-3-(1,1-
26 dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-
27 9H-dibenzo[b,d]pyran-9-one).

1 (f) Immediate precursors. Any material, compound, mixture, or
2 preparation containing any quantity of the following substances:

3 (1) Immediate precursor to amphetamine and
4 methamphetamine:

5 (A) phenylacetone (other names: phenyl-2-propanone;
6 P2P; benzyl methyl ketone; methyl benzyl ketone);

7 (2) Immediate precursors to phencyclidine (PCP):

8 (A) 1-phenylcyclohexylamine; and

9 (B) 1-piperidinocyclohexanecarbonitrile (PCC).

10 (3) Immediate precursor to fentanyl:

11 (A) 4-anilino-N-phenethylpiperidine (ANPP).”

12 **Section 4.** APPENDIX C of Chapter 67, Title 9, Guam Code Annotated, is
13 hereby *amended* to read:

14 “(a) Stimulants. Any material, compound, mixture, or preparation
15 which contains any quantity of the following substances having a stimulant
16 effect on the central nervous system, including its salts, isomers (whether
17 optical, positional, or geometric), and salts of such isomers whenever the
18 existence of such salts, isomers, and salts of isomers is possible within the
19 specific chemical designation:

20 (1) Those compounds, mixtures, or preparations in dosage
21 unit form containing any stimulant substance included in Schedule II
22 which compounds, mixtures, or preparations were listed as an
23 excepted compound on August 25, 1971, pursuant to the federal
24 Controlled Substances Act, and any other drug of the quantitative
25 composition shown in that list for those drugs or which is the same
26 except for containing a lesser quantity of controlled substances;

27 (2) benzphetamine;

1 (3) chlorphentermine;

2 (4) clortermine; and

3 (5) phendimetrazine.

4 (b) Depressants. Any material, compound, mixture, or preparation
5 containing any quantity of the following substances having a depressant effect
6 on the central nervous system:

7 (1) any compound, mixture, or preparation containing:

8 (A) amobarbital;

9 (B) secobarbital; and

10 (C) pentobarbital; or any salt thereof and one or more
11 other active medicinal ingredients which are not listed in any
12 schedule.

13 (2) any of the following drugs, or their salts, in suppository
14 dosage form, approved by the Federal Food and Drug Administration
15 for marketing only as a suppository:

16 (A) amobarbital;

17 (B) secobarbital; and

18 (C) pentobarbital.

19 (3) a substance containing any quantity of a derivative of
20 barbituric acid or any salt of a derivative of barbituric acid;

21 (4) chlorhexadol;

22 (5) embutramide;

23 (6) any drug product containing gamma hydroxybutyric acid,
24 including its salts, isomers, and salts of isomers, for which an
25 application is approved under Section 505 of the Federal Food, Drug,
26 and Cosmetic Act;

1 (7) ketamine, its salts, isomers, and salts of isomers (other
2 names: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone);

3 (8) lysergic acid;

4 (9) lysergic acid amide;

5 (10) methyprylon;

6 (11) perampanel, and its salts, isomers and salts of isomers.

7 (12) sulfondiethylmethane;

8 (13) sulfonethylmethane;

9 (14) sulfonmethane;

10 (15) tiletamine and zolazepam, or any salt thereof (Some trade
11 or other names for a tiletamine-zolazepam combination product:
12 Telazol; (Some trade or other names for tiletamine: 2-(ethylamino)-2-
13 (2-thienyl)-cyclohexanone. Some trade or other names for zolazepam:
14 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-*e*] [1,4]-
15 diazepin-7(1*H*)-one, flupyrzapon);

16 (c) Nalorphine.

17 (d) Narcotic Drugs.

18 (1) Any material, compound, mixture, or preparation
19 containing any of the following narcotic drugs, or their salts calculated
20 as the free anhydrous base or alkaloid, in limited quantities as set forth
21 below:

22 (A) not more than 1.8 grams of codeine per 100
23 milliliters or not more than 90 milligrams per dosage unit, with
24 an equal or greater quantity of an isoquinoline alkaloid of opium;

25 (B) not more than 1.8 grams of codeine per 100
26 milliliters or not more than 90 milligrams per dosage unit, with

1 one or more active, nonnarcotic ingredients in recognized
2 therapeutic amounts;

3 (C) not more than 300 milligrams of dihydrocodeine
4 (hydrocodone) per 100 milliliters or not more than 15 milligrams
5 per dosage unit, with one or more active-nonnarcotic ingredients
6 in recognized therapeutic amounts;

7 (D) not more than 1.8 grams of Dihydrocodeine
8 (hydrocodone) per 100 milliliters or not more than 90 milligrams
9 per dosage unit, with one or more active-nonnarcotic ingredients
10 in recognized therapeutic amounts;

11 (E) not more than 300 milligrams of ethylmorphine per
12 100 milliliters or not more than 15 milligrams per dosage unit,
13 with one or more active, nonnarcotic ingredients in recognized
14 therapeutic amounts;

15 (F) not more than 500 milligrams of opium per 100
16 milliliters or per 100 grams, or not more than 25 milligrams per
17 dosage unit, with one or more active, nonnarcotic ingredients in
18 recognized therapeutic amounts;

19 (G) not more than 50 milligrams of morphine per 100
20 milliliters or per 100 grams with one or more active,
21 nonnarcotic ingredients in recognized therapeutic amounts; and

22 (H) not more than 50 milligrams of morphine per 100
23 milliliters or per 100 grams with one or more active, nonnarcotic
24 ingredients in recognized therapeutic amounts.

25 (2) Any material, compound, mixture, or preparation
26 containing any of the following narcotic drugs or their salts as set below:

27 (A) buprenorphine;

1 (e) Anabolic Steroids. Any drug or hormonal substance chemically
2 and pharmacologically related to testosterone (other than estrogens,
3 progestins, corticosteroids, and dehydroepiandrosterone), and includes:

- 4 (1) $3\beta,17$ -dihydroxy- 5α -androstane;
- 5 (2) $3\alpha,17\beta$ -dihydroxy- 5α -androstane;
- 6 (3) 5α -androstan- $3,17$ -dione;
- 7 (4) 1-androstenediol ($3\beta,17\beta$ -dihydroxy- 5α -androst-1-ene);
- 8 (5) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy- 5α -androst-1-ene);
- 9 (6) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene;
- 10 (7) 5-androstenediol ($\beta,17\beta$ -dihydroxy-androst-5-ene);
- 11 (8) 1-androstenedione ($[5\alpha]$ -androst-1-en- $3,17$ -dione);
- 12 (9) 4-androstenedione (androst-4-en- $3,17$ -dione);
- 13 (10) 5-androstenedione (androst-5-en- $3,17$ -dione);
- 14 (11) bolasterone ($7\alpha,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-
15 en-3-one);
- 16 (12) boldenone (17β -hydroxyandrost-1,4-diene-3-one);
- 17 (13) boldione (androsta-1,4-diene- $3,17$ -dione);
- 18 (14) calusterone ($7\beta,17\alpha$ -dimethyl- β -hydroxyandrost-4-en-3-
19 one);
- 20 (15) clostebol (4-chloro- 17β -hydroxyandrost-4-en-3-one);
- 21 (16) dehydrochloromethyltestosterone (4-chloro- 17β -
22 hydroxy- 17α -methyl-androst-1,4-dien-3-one);
- 23 (17) desoxymethyltestosterone (17α -methyl- 5α -androst-2-en-
24 17β -ol) (Also known as, "madadol");
- 25 (18) $\Delta 1$ -dihydrotestosterone (Also known as, "1-
26 testosterone") (17β -hydroxy- 5α -androst-1-en-3-one);

- 1 (19) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
- 2 (20) drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-
- 3 one);
- 4 (21) ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
- 5 (22) fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -
- 6 dihydroxyandrost-4-en-3-one);
- 7 (23) formebolone (2-formyl-17 α -methyl-11 α ,17 β -
- 8 dihydroxyandrost-1,4-dien-3-one);
- 9 (24) furazabol (17 α -methyl-17 β -hydroxyandrostando[2,3-c]-
- 10 furazan);
- 11 (25) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
- 12 (26) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-
- 13 one);
- 14 (27) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-
- 15 en-3-one);
- 16 (28) mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-
- 17 one);
- 18 (29) mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-
- 19 one);
- 20 (30) methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-
- 21 dien-3-one);
- 22 (31) methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-
- 23 ene);
- 24 (32) methasterone (2 α ,17 α -dimethyl-5 α -androstan-17 β -ol-3-
- 25 one);

- 1 (33) methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-
2 one);
- 3 (34) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane;
4 (35) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane;
5 (36) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
6 (37) 17 α -methyl-4-hydroxynandrolone(17 α -methyl- 4-
7 hydroxy-17 β -hydroxyestr-4-en-3-one);
- 8 (38) methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-
9 dien-3-one);
- 10 (39) methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-
11 trien-3-one);
- 12 (40) methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-
13 en-3-one);
- 14 (41) mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-
15 one);
- 16 (42) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy- 17 α -
17 methyl-5 α -androst-1-en-3- one) (Also known as, "17- α -methyl-1-
18 testosterone");
- 19 (43) nandrolone (17 β -hydroxyestr-4-en-3-one);
20 (44) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
21 (45) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
22 (46) 19-nor-5-androstenediol (3 β , 17 β -dihydroxyestr-5-ene);
23 (47) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
24 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-
25 3,17-dione);
- 26 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

- 1 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 2 (51) norbolethone (13 β , 17 α -diethyl-17 β -hydroxygon-4-en-
- 3 3-one);
- 4 (52) norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
- 5 (53) norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-
- 6 one);
- 7 (54) normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-
- 8 one);
- 9 (55) oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-
- 10 androstan-3-one);
- 11 (56) oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-
- 12 en-3-one);
- 13 (57) oxymetholone (17 α -methyl-2-hydroxymethylene-17 β -
- 14 hydroxy- [5 α]-androstan-3-one);
- 15 (58) prostanazol (17 β -hydroxy-5 α androstano[3,2-c]pyrazole);
- 16 (59) stanozolol (17 α -methyl-17 β -hydroxy-[5 α -androst-2-
- 17 eno[3,2-c]-pyrazole);
- 18 (60) stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-
- 19 one);
- 20 (61) testolactone (13-hydroxy-3-oxo-13,17 secoandrosta-1,4-
- 21 dien-17-oic acid lactone);
- 22 (62) testosterone (17 β -hydroxyandrost-4-en-3-one);
- 23 (63) tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-
- 24 4,9,11-trien-3-one);
- 25 (64) trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one); and

1 (65) Any salt, ester, or ether of a drug or substance described
2 or listed in this Subsection (e) of this Section. Except such term does
3 not include an anabolic steroid that is expressly intended for
4 administration through implants to cattle or other nonhuman species
5 and which has been approved by the Secretary of Health and Human
6 Services for such administration. If any person prescribes, dispenses,
7 or distributes such steroid for human use, such person shall be
8 considered to have prescribed, dispensed, or distributed an anabolic
9 steroid within the meaning of this paragraph. DPHSS may exempt by
10 rule a compound, mixture, or preparation containing a stimulant or
11 depressant substance listed in subsections A and B from the application
12 of all or part of this Act, if the compound, mixture, or preparation
13 contains one or more active medicinal ingredients not having a
14 stimulant or depressant effect on the central nervous system and the
15 admixtures are in combinations, quantity, proportion, or concentration
16 that vitiate the potential for abuse of the substances having a stimulant
17 or depressant effect on the central nervous system.

18 (f) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil
19 and encapsulated in a soft gelatin capsule in a U.S. Food and Drug
20 Administration approved product (Some other names for dronabinol: (6a*R*-
21 *trans*)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6*H*-ibenzo[*b,d*]pyran-
22 1-ol]).”

23 **Section 5.** APPENDIX D of Chapter 67, Title 9, Guam Code Annotated, is
24 hereby *amended* to read:

25 “(a) Narcotic drugs. Any material, compound, mixture, or preparation
26 containing any of the following narcotic drugs, or their salts calculated as the
27 free anhydrous base or alkaloid, in limited quantities as set forth below:

1 (1) not more than 1 milligram of difenoxin and not less than
2 25 micrograms of atropine sulfate per dosage unit;

3 (2) dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-
4 diphenyl-3-methyl-2-propionoxybutane); and

5 (3) 2-[(dimethylamino)methyl]-1-(3-
6 methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers
7 and salts of these isomers (including tramadol).

8 (b) Depressants. Any material, compound, mixture, or preparation
9 which contains any quantity of the following substances, including any salts,
10 isomers, and salts of isomers whenever the existence of such salts,
11 isomers, and salts of isomers is possible within the specific chemical
12 designation:

- 13 (1) alfaxalone;
- 14 (2) alprazolam;
- 15 (3) barbital;
- 16 (4) brexanolone;
- 17 (5) bromazepam;
- 18 (6) camazepam;
- 19 (7) carisoprodol;
- 20 (8) chloral betaine;
- 21 (9) chloral hydrate;
- 22 (10) chlordiazepoxide;
- 23 (11) clobazam;
- 24 (12) clonazepam;
- 25 (13) clorazepate;
- 26 (14) clotiazepam;
- 27 (15) cloxazolam;

- 1 (16) delorazepam;
- 2 (17) diazepam;
- 3 (18) dichloraphenazone;
- 4 (19) estazolam;
- 5 (20) ethchlorvynol;
- 6 (21) ethinamate;
- 7 (22) ethyl loflazepate;
- 8 (23) fludiazepam;
- 9 (24) flunitrazepam;
- 10 (25) flurazepam;
- 11 (26) fospropofol;
- 12 (27) halazepam;
- 13 (28) haloxazolam;
- 14 (29) ketazolam;
- 15 (30) loprazolam;
- 16 (31) lorazepam;
- 17 (32) lormetazepam;
- 18 (33) mebutamate;
- 19 (34) medazepam;
- 20 (35) meprobamate;
- 21 (36) methohexital;
- 22 (37) methylphenobarbital (mephobarbital);
- 23 (38) midazolam;
- 24 (39) nimetazepam;
- 25 (40) nitrazepam;
- 26 (41) nordiazepam;
- 27 (42) oxazepam;

- 1 (43) oxazolam;
- 2 (44) petrichloral;
- 3 (45) phenobarbital;
- 4 (46) pinazepam;
- 5 (47) prazepam;
- 6 (48) quazepam;
- 7 (49) suvorexant;
- 8 (50) temazepam;
- 9 (51) tetrazepam;
- 10 (52) triazolam;
- 11 (53) zaleplon;
- 12 (54) zolpidem; and
- 13 (55) zopiclone.

14 (c) Fenfluramine. Any material, compound, mixture, or preparation
15 which contains any quantity of the following substances, including its salts,
16 isomers (whether optical, position, or geometric), and salts of such isomers,
17 whenever the existence of such salts, isomers, and salts of isomers is possible:

- 18 (1) fenfluramine.

19 (d) Lorcaserin. Any material, compound, mixture, or preparation
20 which contains any quantity of the following substances, including its salts
21 isomers and salts of such isomers, whenever the existence of such salts,
22 isomers, and salts of isomers is possible:

- 23 (1) lorcaserin.

24 (e) Stimulants. Any material, compound, mixture, or preparation
25 containing any quantity of the following substances having a stimulant effect
26 on the central nervous system, including their salts, isomers, and salts of
27 isomers:

- 1 (1) cathine ((+)-norpseudoephedrine);
- 2 (2) diethylpropion;
- 3 (3) fencamfamin;
- 4 (4) fenproporex;
- 5 (5) mazindol;
- 6 (6) mefenorex;
- 7 (7) modafinil;
- 8 (8) pemoline (including organometallic complexes and
- 9 chelates thereof);
- 10 (9) phentermine;
- 11 (10) pipradrol;
- 12 (11) sibutramine;
- 13 (12) solriamfetol (2-amino-3-phenylpropyl carbamate;
- 14 benzenepropanol, beta-amino-carbamate (ester)); and
- 15 (13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

16 (f) Other substances. Any material, compound, mixture, or
17 preparation containing any quantity of the following substance, including its
18 salts:

- 19 (1) pentazocine;
- 20 (2) butorphanol (including its optical isomers); and
- 21 (3) eluxadoline (5-[[[(2*S*)-2-amino-3-[4-aminocarbonyl]-2,6-
- 22 dimethylphenyl]-1-oxopropyl][(*IS*)-1-4-phenyl-1*H*-imidazol-2-
- 23 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) including its optical
- 24 isomers and salts of isomers.

25 (g) DPHSS may exempt by rule any compound, mixture, or
26 preparation containing a depressant substance listed in subsection B from the
27 application of all or part of this Act, if the compound, mixture, or preparation

1 contains one or more active medicinal ingredients not having a depressant
2 effect on the central nervous system and the admixtures are in combinations,
3 quantity, proportion, or concentration that vitiate the potential for abuse of the
4 substances having a depressant effect on the central nervous system.”

5 **Section 6.** APPENDIX E of Chapter 67, Title 9, Guam Code Annotated, is
6 hereby *amended* to read:

7 “(a) Narcotic drugs. Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or preparation containing
9 any of the following narcotic drugs and their salts, as set forth below:

10 (b) Narcotic drugs containing non-narcotic active medicinal
11 ingredients. Any compound, mixture, or preparation containing any of the
12 following narcotic drugs, or their salts calculated as the free anhydrous base
13 or alkaloid, in limited quantities as set forth below, which shall include one or
14 more non-narcotic active medicinal ingredients in sufficient proportion to
15 confer upon the compound, mixture, or preparation, valuable medicinal
16 qualities other than those possessed by the narcotic drug alone:

17 (1) not more than 200 milligrams of codeine per 100
18 milliliters or per 100 grams;

19 (2) not more than 100 milligrams of dihydrocodeine per 100
20 milliliters or per 100 grams;

21 (3) not more than 100 milligrams of ethylmorphine per 100
22 milliliters or per 100 grams;

23 (4) not more than 2.5 milligrams of diphenoxylate and not less
24 than 25 micrograms of atropine sulfate per dosage unit;

25 (5) not more than 100 milligrams of opium per 100
26 milliliters or per 100 grams; and

1 (6) not more than 0.5 milligram of difenoxin and not less
2 than 25 micrograms of atropine sulfate per dosage unit.

3 (c) Stimulants. Any material, compound, mixture, or preparation
4 containing any quantity of the following substances having a stimulant effect
5 on the central nervous system, including their salts, isomers and salts of
6 isomers:

7 (1) pyrovalerone.

8 (d) Depressants. Any material, compound, mixture, or preparation
9 which contains any quantity of the following substances having a depressant
10 effect on the central nervous system, including its salts:

11 (1) brivaracetam ((S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-
12 yl]butanamide) (also referred to as BRV; UCB-34714; Briviact)
13 including its salts;

14 (2) cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-
15 yl)ethyl]carbamate; 2*H*-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-,
16 carbamate(ester), (alpha*R*)-; carbamic acid (*R*)-(+)-1-(2-
17 chlorophenyl)-2-(2*H*-tetrazol-2-yl)ethyl ester);

18 (3) ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-
19 phenyl]-carbamic acid ethyl ester];

20 (4) lacosamide [(*R*)-2-acetoamido-*N*-benzyl-3-methoxy-
21 propionamide];

22 (5) lasmiditan [2,4,6-trifluoro-*N*-(6-(1-methylpiperidine-4-
23 carbonyl)pyridine-2-yl)-benzamide]; and

24 (6) pregabalin [(*S*)-3-(aminomethyl)-5-methylhexanoic
25 acid].”

26 **Section 7. Severability.** If any provision of this Act or its application to any
27 person or circumstance is held invalid, the invalidity does not affect other provisions

1 or applications of this Act that can be given effect without the invalid provision or
2 application, and to this end the provisions of this Act are severable.